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5Abstract
In Vivo Studies on the Transcriptional and Posttranslational
Regulation of the CCAAT/Enhancer Binding Protein β
The transcription factor CCAAT/enhancer binding protein β (C/EBPβ) gene has
CREB responsive elements (CRE) in its promoter, and its transcription is regulated by
CREB during adipogenesis. We have generated a mouse line with a deletion of the CRE
elements on the C/EBPβ promoter and studied the role of these elements in macrophages.
We show that the CREs are important for the induction of C/EBPβ expression following
treatment of the macrophages with IFNγ/LPS. Moreover, we found two novel targets for
C/EBPβ transcription in macrophages, that are macrophage scavenger receptor 1 (Msr1)
and interleukin 13 receptor α1 (IL13α1). We also show that the well-known regulation of
the arginase 1 gene by C/EBPβ is dependent on the ability of CREB to upregulate
C/EBPβ. FACS analyses on our bone marrow-derived macrophage population, showed
that the cells are Mac1(+), F4/80(+) and Gr1(+), typical markers of Natural Suppressor
macrophages. Taken together, the C/EBPβ target genes found in the macrophage and the
cell surface markers, suggest an immunosuppressive phenotype. We propose a novel role
for C/EBPβ in mediating the molecular switch from inflammatory to immunosuppressive
macrophages.
In a separate project, we study the role of the Thr188 and Ser176, Ser180 and Ser184
phopshorylation sites, which are located in the regulatory domain of the C/EBPβ protein.
Thr188 is a known MAPK phosphorylation site, whereas the three serines, whether all or
some, were recently shown to be targets for GSK3β phosphorylation. We created two
mouse lines in which either Thr188, or the three serines were mutated to alanines. We
analyzed the expression of the mutant C/EBPβ  in various tissues, as well as the
expression of C/EBPβ target genes in primary macrophages from both the mouse lines.
We found that the three serines have a role in modulating C/EBPβ’s autoregulatory loop
as well as in reducing the transcription factor’s transactivational activity. Moreover,
based on the migration pattern of the mutant C/EBPβ proteins, we propose a model
suggesting cooperativity between the MAPK and GSK3β  phosphorylation sites. We
conclude that the phosphorylation sites in question are implicated, whether directly or
indirectly, in the modulation of the transcription factor’s activity.
6Zusammenfassung
In Vivo Studien zur transkriptionalen und posttranslationalen
Regulation des CCAAT/Enhancer Binding Proteins β
Das Gen des Transkriptionsfaktors CCAAT/enhancer binding Protein β∗ (C/EBPβ)
besitzt CREB sensitive Elemente (CRE) in der Promotorregion. Die Transkription dieses
Gens wird in der Adipogenese durch CREB reguliert. Es wurde ein Mausstamm
generiert, bei dem die CRE Elemente des C/EBPβ-Promotors entfernt wurden. Die Rolle
dieser Elemente wurde in Makrophagen untersucht. Es wird gezeigt, dass diese CREs
wichtig sind für die Induktion der C/EBPβ-Expression nach Stimulierung von
Makrophagen mit IFNγ/LPS. Darüber hinaus wurden zwei neue Gene gefunden, deren
Transkription von C/EBPβ reguliert wird, der Makrophagen scavenger receptor 1 (Msr1)
und Interleukin 13 Rezeptor α1 (IL13α1). Des weiteren wird gezeigt, dass die bereits
bekannte Regulation des Arginase 1 Gens durch C/EBPβ von einer CREB induzierten
Aktivierung der C/EBPβ Transkription abhängig ist. FACS Analyse zeigte, dass aus
Knochenmark gewonnene Makrophagen Populationen positiv für typische Marker der
Natural Suppressor (NS) Makrophagen (Mac1, F4/80 und Gr1) waren. Die gefundenen
C/EBPβ-regulierten Gene in Makrophagen und die Zelloberflächenmarker legen nahe,
dass es sich um einen Mausphänotyp mit eingeschränktem Immunsystem handelt.
In einem weiteren Projekt wurde die Rolle der Kinasesubstrate Ser176, Ser180, Ser
184 und Thr188 untersucht. Diese Aminosäuren befinden sich in der regulatorischen
Untereinheit des C/EBPβ Proteins. Thr188 ist eine bekannte Phosphorylierungsstelle für
MAPK, während die drei Serine zumindest teilweise von GSK3β phosphoryliert werden.
Es wurden Mausstämme generiert, bei denen entweder Thr188 oder die drei Serine zu
Alaninen mutiert wurden. Die Expression der C/EBPβ Mutanten wurde in verschiedenen
Geweben und die Expression von C/EBPβ-regulierten Genen in primären Makrophagen
der beiden Mausstämme untersucht. Die drei Serine spielen eine Rolle sowohl bei der
Modulation der autoregulatorischen Schleife, als auch bei der Verringerung der Aktivität
des Transkriptionsfaktors. Das Migrationsmuster der mutierten C/EBPβ Proteine legte
einen synergistischen Effekt der Phosphorylierung durch MAPK und GSK3β nahe. Aus
den Ergebnissen kann geschlossen werden, dass die Phosphorylierungsstellen entweder
direkt oder indirekt die Aktivität des Transkriptionsfaktors modulieren.
                                                 
∗ Die Namen der Proteine werden aus dem Englischen übernommen (kursiv), um die allgemein
verwendeten Abkürzungen beibehalten zu können und um Unklarheiten in bezug auf die englische
Originalliteratur zu vermeiden.
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1. INTRODUCTION
Transcription factors are versatile proteins that are able to interpret environmental
signals and convert them into specific changes in gene expression. The target genes for
one transcription factor are multiple, and the circumstances in which they are turned on
can vary and in certain cases appear to be contrasting. A transcription factor has to know
which of its targets it must switch on in a particular moment, as well as to what degree
the transcription must take place and when it must stop. It is evident that transcription
factors are highly specialized in their functions, and therefore must be studied in a
circumscribed environment and under limited conditions at a time.
This thesis is a study on the transcriptional regulation of the C/EBPβ transcription
factor, and how certain posttranslational modifications of the C/EBPβ protein can
modulate its function. Most of the work was carried out in macrophages, a choice that led
us to new discoveries on the role of this transcription factor in immunity. For the sake of
clarity, I will first give an overview of the immune system, with a focus on macrophages,
and then I will describe C/EBPβ per se, as well as in the context of the macrophage.
1.1 The Hematopoietic System
All the cellular elements of the blood derive from the same progenitor, the
hematopoietic stem cells in the bone marrow (Orkin, 1995). Hematopoietic stem cells
initially give rise to stem cells of more limited potential, called multipotent progenitors.
The multipotent progenitor generates the common lymphoid progenitor (CLP) and
common myeloid progenitor (CMP), which proliferate and differentiate into the
immature, and finally mature, cells of the blood and the immune system. Hematopoietic
cells include at least nine mature cell types that are distinct in both morphology and
function (figure 1.1).
INTRODUCTION
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Figure 1.1: Schematic representation of hematopoiesis. Hematopoietic stem cells in the bone
marrow can either self-renew, or differentiate into progenitors that generate precursors of the
myeloid or the lymphoid lineage. The commitment process is characterized by massive cell
proliferation in the early phase followed by successive restriction to distinct cell lineages and to
cell differentiation.
1.1.1  The Lymphoid Lineage
The CLP is capable of differentiating into Natural Killer (NK) cells, B lymphocytes,
and T lymphocytes, depending on the compartment in which differentiation takes place.
NK cells originate in the bone marrow and then emigrate to the peripheral blood. These
lymphoid cells lack antigen specific receptors and are part of the innate immune system
(Blach-Olszewska, 2005). They are important in the killing of cellular targets, such as
tumor cells. An NK cell kills a target cell either by releasing perforin, which damages the
target cell membrane leading to death, or by inducing apoptosis. B lymphocytes develop
in the bone marrow, and are able to rearrange genes encoding for immunoglobulins,
which they express on the cell surface, in order to obtain antigen specificity. When B
lymphocytes are activated, they differentiate into plasma cells and secrete antibodies.
Although B cells are important mediators of immunity, for the scope of this thesis, I will
concentrate on T lymphocytes as far as the lymphoid lineage is concerned.
In the thymus, the CLP differentiates into CD4(+)CD8(+) T cells. CDs are
hematopoietic cell surface markers, and in particular CD4 and CD8 are receptors
expressed on the T cell membrane. Thymocytes that recognize self antigens are
eliminated by apoptosis, ensuring the selection of T cells that recognize a wide variety of
foreign antigens in conjunction with the major histocompatibility complex (MHC)
(Robey and Fowlkes, 1994). Finally, the T cell matures by downregulating the expression
of either the CD4 or the CD8 coreceptors, upregulating the expression of CD3, and
CLP
CMP
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leaving the thymus to populate peripheral lymphoid organs (Scollay, 1991). Peripheral T
cells circulate in a quiescent state until they encounter an antigen-presenting cell (APC)
bearing a cognate antigenic peptide bound to an appropriate MHC molecule (Crabtree,
1989). Engagement of the T cell receptor complex by the peptide-MHC complex results
in T cell activation. CD8(+) or cytotoxic T cells are capable of killing cells infected with
viruses. So called CD4(+) T helper lymphocytes differentiate into two distinct subsets
upon T cell receptor engagement, named T helper 1 (Th1) and T helper 2 (Th2)
(Mossman et al., 1986). Th1 cells are responsible for cell-mediated, inflammatory
immunity, including the activation of inflammatory macrophages, while Th2 cells
contribute to humoral responses, activate mast cells and eosinophils, and often exhibit
antiinflammatory properties. The two subsets of T helper cells can be distinguished by
different patterns of secreted cytokines. In general, Th1 cells produce IL2 (interleukin 2),
IFNγ (interferon γ) and TNFβ (tumor necrosis factor β), whereas Th2 cells produce the
interleukins IL4, IL5, IL10 and IL13.
T cells are responsible for activating other cells of the immune system, such as the
macrophages. Th1 and Th2 T cells can elicit very different responses from macrophages,
and this property will be described further on.
1.1.2 The Myeloid Lineage
The common myeloid progenitors give rise to either megakaryocyte/erythrocyte
progenitors (MEP) or granulocyte/monocyte progenitors (GMP) (Akashi et al., 2000).
The transcription factors PU.1 and C/EBPα are responsible for normal myeloid
differentiation from stem cells to monocytes or granulocytes (Behre et al., 1999). In
particular, PU.1 induces expression of the MCSF (macrophage colony stimulating factor)
receptor and the development of monocytes, whereas C/EBPα increases the expression of
the GCSF (granulocyte colony stimulating factor) receptor and leads to mature
granulocytes.
Megakaryocytes are the precursors of platelets, which play a fundamental role in
blood clotting and wound healing. Erythrocytes are enucleated red blood cells, which
contain haemoglobin, and are essential for delivering oxygen to tissues, in exchange for
CO2, which is discharged in the lungs.
 Granulocytes have densely staining granules in their cytoplasm and they are
sometimes called polymorphonuclear leukocytes, because of their oddly shaped nuclei.
There are three types of granulocytes and they are called neutrophils, eosinophils and
basophils. Neutrophils are phagocytic cells and they are the most numerous cellular
component of the innate immune system. If on one hand C/EBPα is important for
granulocyte maturation, other C/EBP family members (i.e. C/EBPβ, -δ, and -ζ) increase
at the stage where proliferation ceases in neutrophils (Bjerregaard et al., 2003).
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Moreover, C/EBPε is involved in the expression of specific granules in neutrophils.
Eosinophils are thought to be important in defense against parasitic infections. The
function of basophils is still largely unclear, but it is probably complementary to that of
eosinophils.
1.1.3 Macrophages
Macrophages are the mature form of monocytes. Monocytes are generated in the bone
marrow by a granulocyte/monocyte progenitor, which has gone through two stages of
differentiation involving the formation of monoblasts and promonocytes. Newly
produced monocytes are released into the blood where they circulate for 1-3 days and
subsequently undergo differentiation into macrophages upon migration from the capillary
bed to extravascular tissues (Volkman and Gowans, 1965). An increase in the expression
of macrophage-associated antigens CD71 (i.e. the transferrin receptor), CD14 and CD11
(also called Mac1), after 3-7 days of culture in vitro, define a time-dependent
differentiation of monocytes to macrophages (Gessani et al., 1993). Antibodies against
Mac1 (or CD11b), which is a granulocyte/macrophage-specific integrin molecule, are
often used as markers for myeloid cells. F4/80 is another commonly used antibody,
which detects a member of the epidermal growth factor (EGF)-transmembrane 7 (TM7)
family (MacKnight and Gordon, 1998). Although the function of the molecule has
remained elusive, it was recognized as a murine macrophage-specific surface marker.
1.1.4  Mechanisms of Phagocytosis in Macrophages
Macrophages are distributed widely in the body tissues, where they play a critical role
in innate immunity, but also participate in acquired immunity. They are essential in the
humoral immune response because, like neutrophils, they are phagocytic.  In other words,
a macrophage can bind a pathogenic particle to the surface of the cell, internalize it and
destroy it (reviewed in Aderem and Underhill, 1999). This property is not only
fundamental for triggering an inflammatory response upon microbial infections, but also
for clearing out apoptotic cells and exerting anti-tumoral functions. Macrophages are
often found to be involved in the infection of parasites such as helminths (MacDonald et
al., 1999) and protozoa, such as Trypanosoma, Plasmodium, and many others. At first the
macrophage engulfs a parasite to protect the organism, but often it can become the target
for the infection by the parasite, who subverts typical macrophage antimicrobial functions
and exploits the antiinflammatory effects (Denkers and Butcher, 2005).
Phagocytosis can involve different receptor molecules on the surface of the
macrophage, defining two distinct immune response pathways. The innate immune
response is mediated by a direct recognition of the pathogen by the macrophage and does
not involve other immune cells. The acquired immune response involves phagocytosis of
INTRODUCTION
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particles via antibody receptors and the reciprocal activation with T cells mediated by
antigen presentation. Examples are given below.
LPS (lipopolysaccharide) is the polysaccharide that coats gram-negative bacteria
(Raetz et al., 1990). The lipid A domain (or endotoxin) of LPS is a glucosamine-based
phospholipid that makes up the outer monolayer of the outer membrane of the bacteria.
Endotoxin is recognized by a lipopolysaccharide binding protein (LBP), a 50kDa
polypeptide synthesized in hepatocytes and released in a 60kDa glycosylated form in the
plasma. LBP serves as an opsonin, which strongly enhances the recognition of LPS by
macrophages. CD14 was identified as the receptor for LPS-LBP complexes (Wright et
al., 1990), and can be considered a mediator of macrophage innate immunity. It was only
in 1999 that Chow and coworkers demonstrated that TLR4 (Toll-like receptor 4) is
involved in lipopolysaccharide signaling and serves as a cell-surface coreceptor for
CD14. TLR4 was found to interact physically with MD2, an additional component of the
LPS signaling pathway (Shimazu et al., 1999). TLR signaling relies on the function of
the intracellular adaptor protein MyD88, which presumably acts in conjunction with other
TLR-specific adaptor proteins, such as Tollip and Mal (Janssens et al., 2003) (figure 1.2).
These adaptor proteins are necessary for the recruitment and activation of different IL1
receptor-associated kinase (IRAK) family proteins, which further transmit the signal.
This leads to activation of the IκB kinase complex and mitogen-activated protein kinases
(c-Jun N-terminal kinase/p38), which induce NFκB and AP-1-dependent gene
transcription, respectively. Biophysical approaches used to study intramolecular
interactions revealed that LPS is associated with non-TLR-related molecules as well,
ranging from integrins such as CD11b/CD18 to chemokine receptors, scavenger
Figure 1.2: Schematic representation of the
LPS signaling pathway. LPS is recognized by
the CD14 receptor, which, in association with
TLR4 and MD2, triggers the intracellular signal.
In the cytoplasm, MyD88 phosphorylates IRAK
and activates a pathway, which leads to
IκB/NFκB activation, and transcription of target
genes. Among the target genes are many
cytokines. (Image taken from glycoforum
website: www.glycoforum.gr.jp)
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receptors, and many others (Triantafilou et al., 2002). Many of these receptors are
clustered upon LPS triggering in lipid rafts, suggesting the formation of supramolecular
LPS activation clusters.
The polysaccharide capsules of bacterial pathogens sometimes allow them to resist
direct engulfment by phagocytes. These bacteria become susceptible to phagocytosis,
however, when they are coated with immunoglobulins (a process called opsonization)
that engages the Fcγ receptors on macrophages, triggering the uptake and destruction of
the bacteria (Indik et al., 1995). The release of specific immunoglobulins comes from B
cells. Because of the involvement of other immune cells, which have produced antibodies
specific for the pathogen, this is an example of acquired immunity. Endocytosis of a
particle by the macrophage leads to its enclosure in an acidified cytoplasmic vesicle,
called phagosome. The phagosome then fuses with one or more lysosomes to generate a
phagolysosome, releasing the lysosomal enzymes into the phagosome interior where they
destroy the bacterium.
1.1.5 The Activation of Macrophages
Macrophages can be activated in vitro by the addition of LPS to the culture medium.
LPS stimulates phagocytes to synthesize cytokines such as TNFα, IL1, and IL6, which
play a role in inflammatory reactions and activation of immune responses (Hermann et
al., 1991). IFNγ, a cytokine produced by T cells during the inflammatory response, is
often used in vitro in combination with LPS to activate macrophages. Through the use of
neutralizing IFNγ-specific monoclonal antibodies and gene-targeted mice, it has been
possible to establish unequivocally the predominant role played by IFNγ in generating
activated macrophages, both in vitro and in vivo (Dalton et al., 1993). On the surface of
the macrophage are receptors specific for IFNγ, called IFNGR1 and 2 (reviewed in Stark
et al., 1998). In unstimulated cells, IFNGR1 associates with Janus kinase (JAK)-1, and
IFNGR2 associates with JAK2. IFNγ induces oligomerization of the IFNγ receptor
subunits, which leads to the transphosphorylation and activation of JAK1 and JAK2. The
activated JAKs then phosphorylate Tyr440 of IFNGR1, creating a docking site for signal
transducer and activator of transcription (STAT) 1. While bound to the receptor, STAT1
is phosphorylated on Tyr701 and is released from the receptor, forming a homodimer that
translocates to the nucleus. The STAT1 homodimer binds to IFNγ-activated site (GAS)
elements present on the promoters of IFNγ-regulated genes, such as IFN γ-regulated
factors (IRFs), to initiate transcription.
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In macrophages LPS and IFNγ synergize in inducing mechanisms to kill microbial
targets. Two of the most important mechanisms involve the production of reactive
oxygen and reactive nitrogen intermediates, during a process called “respiratory burst”
(Bogdan et al., 2000). The production of reactive oxygen intermediates is initiated by
NADPH oxidase with the release of superoxide in the cell, which can be converted to
H2O2 or hydroxyl radicals and hydroxyl anions. Most of these intermediates are toxic to
bacteria. Nitric oxide (NO) is produced by inducible nitric oxide synthase (iNOS) in
macrophages. iNOS converts L-arginine and molecular oxygen to L-citrulline and NO (or
NO radicals and subsequent intermediates). The iNOS gene can be activated via several
signal transduction pathways and molecules, including JAK1/STAT1α/IRF1, IκB/NFκB
and MAPK. The production of NO is also subject to the availability of L-arginine as a
substrate. NO can be toxic to several pathogens, including viruses (Saura et al., 1999),
and their host cells. In addition, both LPS and IFNγ are able to induce IFNβ secretion and
an antiviral state in murine peritoneal macrophages (Gessani et al., 1989).
Activated macrophages express a whole series of phenotype markers essential for
specific effector functions, such as the class II major histocompatibility molecule (MHC
II), macrophage colony-stimulating factor (M-CSF) receptor and Fcγ receptors. MHC II
molecules are heterodimers made of 34 and 28 kDa chains found mainly on the surfaces
of macrophages, B cells, dendritic cells, the Langerhans cells of the skin and lymphoid
organs. Cells expressing MHC II molecules are called antigen-presenting cells (APC).
Once a macrophage has phagocytosed an antigen, it will unfold the proteins and break
them down by partial proteolysis. This process will uncover epitopes which are
recognized by MHC II molecules, which in turn will expose the peptides on the outer
membrane of the macrophage. CD4(+)T-helper cells will recognize the peptides
Figure 1.3: Schematic representation of
the JAK/STAT signaling pathway.
IFNγ binds to its heterodimeric receptor,
which induces reciprocal phosphorylation of
the JAKs. JAKs in turn mediate
phosphorylation of IFNGR1, which becomes
a docking site for STAT1. On the receptor
STAT1 is phosphorylated and released. The
transcription factor then forms a homodimer,
translocates to the nucleus, and recognizes
GAS elements in the promoters of its target
genes (such as IRF1). (Image taken and
readapted from Science Nerd Depot website:
www.sciencenerddepot.com)
IFNGR1 IFNGR2
GAS IRF1
1
Nucleus
Cytoplasm
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presented by APCs and initiate the diverse cellular interactions that result in B cell
activation, development of inflammatory reactions, and activation of CD8(+) cells to
become active killer cells. Interferon γ (IFNγ) is produced by T cells during antigen
presentation and binds to macrophages inducing de novo expression of MHC II
molecules. The whole process subsides as the antigen is eliminated (reviewed in Unanue
and Allen, 1987).
1.1.6 Antiinflammatory Macrophages
The macrophage activation just described is a typical inflammatory response to
stimuli received by Th1 T cells. In general, macrophages induced in Th1-dominated
immune responses, secrete inflammatory cytokines, such as IL1, IL6 and TNFα, and are
called inflammatory macrophages or M1 macrophages (Mills et al., 2000). M1
macrophages possess cytotoxic and antimicrobial effector functions based on their ability
to produce NO (MacMicking et al., 1997). On the contrary, M2 macrophages are elicited
by the Th2 immune response and display antiinflammatory properties. These
macrophages are particularly important in the case of injury, when excessive
inflammation could impair tissue regeneration.
M2 macrophages produce arginase 1, which is an enzyme that converts L-arginine to
L-ornithine and urea (the nitrogen elimination step of the Krebs urea cycle). L-ornithine
can be further processed into polyamines, which nourish cell growth and promote tissue
repair (Jenkinson et al., 1996). M2 cells are believed to attenuate Th1 responses and
induce peripheral tolerance, possibly also to prevent auto-immunity. However, because of
this permissive feature, M2 macrophages are often associated with parasite infections and
tumor progression (Baetselier et al., 2001; Mills et al., 1992).
Arginase 1 and iNOS compete for the same substrate for their reactions, L-arginine
(Modolell et al., 1995). In a way, this bestows on arginase 1 the additional property of
limiting NO synthesis and mediating part of the passage from M1-type to M2-type
macrophage.
1.1.7 Specialized Macrophages
Resident macrophages are distributed constitutively throughout the organism in the
absence of any inflammatory signal and display regional heterogeneity. Functional,
morphological and phenotypic heterogeneity may reflect the acquired environments of
these cells. Only a few examples of specialized macrophages will be given.
The resident macrophages of the liver are called Kupffer cells. Kupffer cells’
responses to LPS and other gut-derived stimuli may be important in their interactions
with hepatocytes (Decker, 1998). These cells could be at least partly responsible for
regulating the acute phase response in injury and malignancy.
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In the spleen there is a heterogeneous population of macrophages (Buckley et al.,
1987), which have different functions according to their localization. They trap and
process antigens in the marginal zone, interact with T and B lymphocytes in the lymphoid
areas (the white pulp), and phagocytose senescent erythrocytes in the red pulp.
Some macrophages penetrate the blood-brain barrier, entering the nervous system
during embryonic development, and are called microglia. Microglia play a role in
removing dying neurons in the developing central nervous system (CNS)(Perry et al.,
1985). Indeed, naturally occurring cell death is a major event in the development of the
CNS, and as much as 50% of the original neuronal population generated in the embryo
may degenerate before maturity. However, the role of microglia in the adult brain is still
a matter of investigation.
Furthermore, there are populations of myeloid cells, which are similar in many ways
to macrophages, but are considered to derive from different differentiation pathways.
Among these are dendritic cells (DC), Langerhans cells and mast cells.
Dendritic cells are characterized by the presence of polarized lamellipodia and long
spiny processes continuously extended and retracted, allowing these cells to be extremely
motile. Motility allows DCs to move from the blood to peripheral tissues and from these
tissues to lymphoid organs, to meet antigen-specific T cells (Banchereau and Steinman,
1998). Immature DCs can internalize efficiently a diverse array of antigens for processing
and loading onto MHC molecules, as a consequence of high endocytic activity (Cella et
al., 1997). As a result, DCs start to mature by accumulating MHC II complexes in
distinctive non-lysosomal vesicles. Finally, in the mature DCs peptide-MHC II
complexes are present stably on the plasma membrane, allowing selection of even rare
antigen-specific T cells, a feature which has earned them the name of professional
antigen presenting cells (APC).
Langerhans cells are the specialized dendritic cells found in the suprabasal layer of
the epidermis (Thorbecke et al., 1980). Like DCs, they are professional APCs, and they
are characterized by a high motility, which enables them to reach local lymph nodes. The
most typical organelles of Langerhans cells are Birbeck granules, which are tennis racket-
shaped bodies that seem to have a role in the transfer of molecules entering the cell via
receptor-mediated endocytosis.
Mast cells reside mainly near small blood vessels and surfaces exposed to the
environment, where pathogens and allergens are frequently encountered (Galli et al.,
2005). They release substances that affect vascular permeability when activated, and are
known for their role in orchestrating allergic responses.
1.1.8 The Role of Macrophages in Atherosclerosis
Macrophages express scavenger receptors on their surface, which recognize modified
(i.e. oxidized or acetylated) low-density lipoproteins (LDL) (Freeman, 1997). These
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receptors are involved in lowering the cholesterol levels in the blood, an event that
mostly occurs in the liver with the help of Kupffer cells (Van Berkel et al., 1991).
However, in some cases the uptake of lipid by macrophages may lead to disease.
The earliest event in the development of atherosclerosis is the adhesion of circulating
monocytes to regions of the lumenal surface of the endothelium of a blood vessel (Ross,
1993). The adhesion occurs through the vascular cell adhesion molecule-1 (VCAM-1).
Signals that induce VCAM-1 expression are unknown, but could be the altered
generation of inflammatory mediators. Once macrophages have been recruited, they can
secrete chemotactic factors to increase the response (Jessup et al., 2002). Adherent
macrophages migrate across the endothelium and reside in the intima. Most of the intimal
macrophages accumulate large intracellular deposits of lipid, which locate in cytoplasmic
fat droplets, giving the cells a foamy appearance. The increasing number of macrophages
that accumulate in the lesion around the lipid core eventually develop into atherosclerotic
plaques. Cellular debris, extracellular lipids and calcium deposits that become part of the
plaque, can make the lesion susceptible to rupture, thereby stimulating platelet deposition
and formation of thrombi.
1.2  The C/EBP Family of Transcription Factors
The first C/EBP protein was identified as a heat-stable factor in rat liver nuclei
capable of interacting with the CCAAT box motif in several gene promoters. The C/EBP
gene was cloned in 1988 (Landschulz et al., 1988) and discovered to possess a basic-
leucine zipper (bZIP) necessary for DNA binding and dimerization, a feature that today
identifies a whole class of transcription factors. In the following years, five other
members of the C/EBP family were identified (reviewed in Ramji and Foka, 2002), and
were named with Greek letters from C/EBPα to -ζ (Table 1).
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Table 1: Cloned C/EBP genes and phenotypic characterization of knockout models. (Taken from
Lekstrom-Himes and Xanthopoulos, 1998)
              
Phenotypic abnormalities
Name Alternative
name
Expression
pattern
KO
model
Hepatic Metabolic Hematologic Other
C/EBPα C/EBP Liver, adipose,
lung ,  adrena l
gland, placenta,
ovary, peripheral
blood
mononuclear cells
yes Hepatocyte
prolifera-
tion,
perinatal
lethal
Defective lipid
storage,
defective
carbohydrate
metabolism
Myeloid
maturation block
at myeloblast
stage
C/EBPβ NF-IL6, LAP,
CRP2,
AGP/EBP,
NF-M
Liver, intestine,
adipose,  lung,
skin ,  myeloid
lineage, ovary,
neurons
yes Hypo-
glycemia
Defective lipid
storage,
defective
carbohydrate
metabolism
(synergistic
with C/EBPδ)
Immunodeficient,
defective Th1
response,
macrophage
phagosome defect
Female
sterility
C/EBPγ Ig/EBP ubiquitous No
C/EBPδ CELF, CRP3,
NF-IL6b,
RcC/EBP2
L i v e r ,  l u n g ,
adipose, intestine,
macrophages
yes None
detected
Defective lipid
storage
(synergistic
with C/EBPβ)
None detected Neuro-
logic
defects
C/EBPε CRP1 M y e l o i d  a n d
lymphoid lineages
yes None
detected
None detected Immunodeficient,
granulocyte
defects, myeloid
proliferation
C/EBPζ CHOP, Gadd 153 ubiquitous yes
All C/EBP isoforms share substantial sequence identity in the C-terminal region,
which contains the bZIP domain. This domain consists of a basic amino acid rich DNA
binding region followed by a dimerization motif called “leucine zipper”. The leucine
zipper is a heptad repeat of four or five leucine residues that assume an α-helical
configuration. Two of these repeats interdigitate to form a coiled-coil structure at the site
of dimerization. The dimer forms an inverted Y structure, in which each arm of the Y
consists of a basic region capable of interacting with one half of the palindromic
recognition sequence in the DNA major groove (Figure 1.4). Because the bZIP domain is
highly conserved, the different C/EBP isoforms can form homo- or heterodimers with all
the intrafamilial combinations. The optimal C/EBP DNA binding site has been shown in
vitro to be a dyad symmetrical repeat A/G TTGCG C/T AA C/T, even though substantial
variations are tolerated (Osada et al., 1996).
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At the N-terminus, C/EBP proteins are more divergent. This is where the trans-
activation domain is situated. The interaction in this region with other transcriptional
coactivators [e.g the SWI/SNF complex for C/EBPα and -β (Pedersen et al., 2001;
Kowentz-Leutz and Leutz, 1999)] and with the basal transcriptional machinery, such as
TBP and TFIID in C/EBPα (Nerlov and Ziff, 1995), will produce transcriptional
activation in a more “isoform specific” manner.
Because of the structural similarity among all the C/EBP family isoforms, it is
frequent to find functional redundancy between the family members, depending on their
coexistence in a specific cell type. In this thesis I will focus on the C/EBPβ transcription
factor, but it is important to keep in mind that the specific function of one family member
can be easily masked by the presence of, or heterodimerization with another isoform.
1.2.1  The C/EBPβ Transcription Factor
The human isoform of C/EBPβ (also called NF-IL6) was first characterized as a
protein that binds to the interleukin-1- responsive element in the promoter of the
interleukin 6 gene and to similar sites in other cytokine genes (Akira et al., 1990). The
C/EBPβ gene is intronless, but contains three different initiation codons that give rise to
three C/EBPβ isoforms of different size from the same mRNA (Descombes and Schibler,
1991) (Figure 1.5). The largest protein, of 38kDa, is called LAP* (liver-enriched
transcriptional-activator protein). The transactivation domain of this isoform contains
four conserved regions, whereas the LAP isoform, 35kDa, has only three, as its start site
is situated just at the end of the first conserved region. LAP is the most commonly found
active C/EBPβ  isoform. A third, short form of C/EBPβ (20kDa), is called LIP (liver-
enriched transcriptional-inhibitory protein), and it lacks all of the transactivation domain.
Figure 1.4: Structure of the C/EBPβ basic region/leucine
zipper domain bound to DNA
The two α-helical basic regions (bottom) dimerize through
the α-helical leucine zipper domain (top) to form an
inverted Y shape structure. Each arm of the Y is formed by
a single α-helix, one from each monomer, which binds to
one half of the palindromic recognition sequence. (Rasmol
structure obtained from the Protein Data Bank entry IH8A.)
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However, LIP has a bZIP domain, and therefore can act as a dominant negative inhibitor
of C/EBP by forming non-functional heterodimers with other family members
(Descombes and Schibler, 1991).
The N- and C-terminal regions of C/EBPβ are characteristic of the C/EBP family and
have already been described. Upstream from the DNA-binding region of the protein is a
regulatory region, which is subdivided in two regulatory domains, called RD1 and RD2.
Posttranslational events take place in these domains, which appear to be important in
modulating the transcription factor’s function. These events are described in detail further
on in this Introduction.
Figure 1.5: Schematic representation of the C/EBPβ protein. The arrows indicate the
alternative start sites that give rise to the different C/EBPβ isoforms. The transactivation domain
is at the N-terminus (TAD) with four conserved regions (CR1-4). RD is the regulatory domain,
divided in two subregions (see below). The basic leucine zipper (bZIP) is composed of a DNA-
binding domain (DBD) and the leucine zipper (LZ).
C/EBPβ expression is particularly high in the liver, adipose tissue, lung, spleen,
intestine, kidney and myelomonocytic cells (Descombes et al., 1990; Poli et al., 1990;
Akira et al., 1990). However, it has also been shown to be expressed in keratinocytes,
where it plays a role in squamous differentiation (Zhu et al., 1999); in the mammary
epithelium, where ductal morphogenesis, lobuloalveolar proliferation, and functional
differentiation take place only in the presence of C/EBPβ (Seagroves et al., 1998;
Robinson et al., 1998); and in hippocampal neurons, where C/EBPβ is associated to long-
term consolidation (Alberini et al., 1994).
Mice deficient for C/EBPβ are viable, although a small subset of pups die perinatally
(Tanaka et al., 1995; Screpanti et al., 1995). The survivors display fasting hypoglycemia,
decreased blood lipids, and impaired hepatic glucose output in response to hormonal
stimulation (Liu et al., 1999). The lack of C/EBPβ causes an impairment in lipid droplet
accumulation in interscapular brown adipose tissue (BAT) of newborn mice (Tanaka et
al., 1997). The weight of epidydimal white adipose tissue (WAT) of mice carrying a
deletion of both C/EBPβ and C/EBPβδ is lower than that of wild type mice. Indeed, also
mice lacking either C/EBPβ or C/EBPβδ tended to have lower epidydimal fat pad weight,
however in this case the difference was not significant.
TAD RD bZip
Lap* Lap Lip
CR3CR2 CR4CR1 DBD LZRD1 RD2
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Female C/EBPβ  knockout mice are sterile due to a defect in ovarian follicle
development (Sterneck et al., 1997). Recently, it has been shown that mice deficient for
Id2, a negative regulator of basic helix–loop–helix (bHLH) transcription factors, exhibit a
defect in lactation due to impaired lobuloalveolar development during pregnancy, very
similar to the mice lacking C/EBPβ, and that Id2 is a target for C/EBPβ transcription
(Karaya et al., 2005). Moreover, overexpression of the LIP inhibitory isoform of C/EBPβ
correlates with breast tumors in humans (Zahnow et al., 2001), and gene expression
profiling analyses in human tumors have shown that C/EBPβ is a principal effector of
cyclin D1 activity in breast carcinomas (Lamb et al., 2003).
 1.2.2 C/EBPβ in Macrophages
Several studies have proven C/EBPβ to play an important role in determining
terminal differentiation and activation of macrophages. The expression of C/EBPα, -β
and -δ is differentially regulated in the myelomonocytic lineage. C/EBPα is expressed in
immature myeloblasts and at very low levels during the process of macrophage
differentiation, a time during which C/EBPβ expression, on the contrary, is strongly
induced (Natsuka et al., 1992). Upon activation of the macrophage, C/EBPα is shut
down, whereas C/EBPβ appears to be important for terminal differentiation and
mediating the immune response. C/EBPδ is also expressed at moderate levels alongside
C/EBPβ in macrophages, however C/EBPδ-deficient mice do not seem to display
immune defects.
One of the first studies on C/EBPβ(-/-) mice demonstrated that C/EBPβ is a critical
transcription factor in bacteria killing and tumor cytotoxicity as well as in the G-CSF
gene induction by macrophages (Tanaka et al., 1995). In particular, it appears that
C/EBPβ deficient mice are more susceptible to Listeria monocytogenes infections than
their wild type litter mates, and that this is due to the fact that the intracellular bacteria are
able to escape from the phagosome to the cytoplasm.
In the same period, another work was published (Screpanti et al., 1995) that showed
that C/EBPβ knockout mice are more susceptible to Candida albicans infection and that
this correlates with an impaired production of IL-12 and a defective release of NO2 anion
by splenic macrophages. Moreover, these mice seem to display an imbalanced T-helper
response attributed to a lymphoproliferative disorder. In particular, the ratio of B cells to
T cells seems to be markedly shifted towards an excess of B cells, or a deficiency in T
cells, which means that the antibody (B cell-mediated) response may be prevailing over
the T lymphocyte-dependent cell-mediated immunity.
Several genes encoding for cytokines and other inflammatory mediators carry on their
promoters C/EBP binding sites and have been reported to be targets for C/EBPβ
transcription. Among these are the cytokines IL-6, TNFα, IL-1β, G-CSF, and IL-12 p40
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(Matsusaka et al., 1993; Pope, 1994; Zhang et al., 1993; Dunn et al., 1994; Plevy et al.,
1997), the chemokines IL-8, macrophage inflammatory protein (MIP) -1α, monocyte
chemoattractant protein-1 (MCP1) (Matsumoto et al., 1998; Bretz et al., 1994), and the
genes encoding lysozyme, cyclooxygenase (COX)-2, and inducible NO synthase (iNOS)
(Goehte et al., 1994; Wadleigh et al., 2000; Lowenstein et al., 1993).
1.2.3 The C/EBPβ Promoter
Deletion studies on a region located upstream of the transcriptional start site of the
C/EBPβ gene, performed by the use of luciferase reporter gene assays, demonstrated that
C/EBPβ expression is directly linked to a small region in its promoter located at -60 to -
120bp (Niehof et al., 1997). Within this region, two sites that are homologous to the
classical CREB regulatory elements (CRE), or CREB consensus sequence, were
identified. These two sites are incomplete CREB-binding DNA motifs, as only five out of
eight nucleotides are conserved compared to the CREB consensus sequence.
Nevertheless, CREB was shown to have binding affinity to CRE-1 and CRE-2 in vitro by
gel shift experiments performed with oligonucleotides carrying the sequence of the
C/EBPβ CREs (Niehof et al., 1997). In vivo, experiments in preadipocytes showed that
increased C/EBPβ gene transcription correlated with the phosphorylation of CREB on
Ser133, and the interaction of CREB with the C/EBPβ CRE elements was shown by
chromatin immunoprecipitation (ChIP) (Zhang et al., 2003). CREB phosphorylation
occurs in response to cAMP (Gonzales et al., 1989), increased intracellular Ca 2+ (Sheng
et al., 1991), and growth factors like nerve growth factor (Ginty et al., 1994).
Phosphorylation of CREB on Ser133 increases its binding to CREB binding protein
(CBP), which mediates the link to the basal transcription machinery and therefore
stimulates transcription of CREB-dependent genes (Kwok et al., 1994).
Moreover, a C/EBP binding site was found to be partially overlapping with CRE-1
(Niehof et al., 2001). This suggests the existence of an autoregulatory loop on the one
hand, but also a synergistic regulation of C/EBPβ expression between C/EBPβ and
CREB. Both transcription factors belong, in fact, to the bZIP class and are likely to be
able to interact. The autoregulatory loop described by Niehof and colleagues is a positive
one. This was shown by the decreased luciferase activity in cells cotransfected with a
C/EBPβ expression vector and a luciferase reporter gene construct carrying the promoter
of C/EBPβ with a mutation in the C/EBP binding site. Previous studies had identified two
other sites, further upstream on the C/EBPβ promoter, to which C/EBPβ protein was
capable of binding upon LPS stimulation of mouse liver cells (Chang et al., 1995).
Interestingly, these C/EBP binding sites were not recognized by other C/EBP family
members, indicating that the regulation loop is specific for C/EBPβ (Mink et al., 1999).
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1.2.4 Posttranslational Modifications of the C/EBPβ Transcription Factor
C/EBPβ is a very rich substrate for posttranslational modifications. Phosphorylation
takes place on numerous residues and is by far the most represented modification.
However, recent studies have demonstrated C/EBPβ to be a substrate for acetylation and
sumoylation. In contrast with the known positive regulatory effects of acetylation on
other transcription factors, Xu and colleagues have shown that IL3-dependent
deacetylation of a lysine residue in the basic region of C/EBPβ contributes to the
induction of the Id1 gene expression in a hematopoietic cell line (Xu et al., 2003). In
other words, acetylation of the basic region of C/EBPβ decreases its DNA binding
affinity. The deacetylation of C/EBPβ seems to be mediated by STAT5, that recruits
HDAC1 on the Id-1 promoter in the presence of C/EBPβ. Concerning sumoylation, the
Williams laboratory has identified a five amino acid motif in the RD1 domain of
C/EBPβ, which is a site for covalent attachment of the small ubiquitin-like modifier-1
(SUMO-1) protein. They show that attachment of SUMO-1 to the lysine within this motif
decreases the transcriptional inhibitory function of the regulatory domain (Kim et al.,
2002).
1.2.5 Modulation of C/EBPβ Activity by Phosphorylation
Phoshporylation plays a key role in the modulation of C/EBPβ function. It has been
reported that C/EBPβ is normally a repressed factor in which negative regulatory regions
mask its transactivation domain. Two regions shortly upstream from the DNA binding
domain on the C/EBPβ protein were shown to repress transactivation, which was strongly
enhanced if the two regions were deleted (Kowenz-Leutz et al., 1994). The two regions
were defined regulatory domains, RD1 and RD2 respectively (Figure 2). Several putative
phosphorylation sites occur in the serine/threonine-rich RD2 sequence and these are good
candidates as mediators of a structural remodeling of the C/EBPβ protein, which could
regulate its function (Williams et al., 1995). However this possibility has not been proven
yet, and must be considered speculative.
What is certain is that phosphorylation occurs at least on two residues of the RD2
domain, and in particular Ser231 and Thr235 of the human isoform (corresponding to Ser
184 and Thr188 in the mouse) of C/EBPβ. This was demonstrated by transient expression
of site-directed mutants on these residues and subsequent phosphopeptide mapping
(Nakajima et al., 1993). In particular, Thr235 was found to be a substrate for MAP kinase
phosphorylation and a target for ras-dependent activation of C/EBPβ. Since mutational
activation of Ras plays an important role in skin tumorigenesis induced by a variety of
carcinogens (Quintanilla et al., 1986), Zhu and coworkers (2002) studied the
susceptibility of C/EBPβ null mice to carcinogen-induced skin tumors involving mutant
Ras. They found that the mice were completely refractory to the tumors, and that v-Ha-
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ras transgenic mice carrying the C/EBPβ-null mutation also showed a significant
reduction in tumorigenesis. Moreover, they showed that Ha-ras-induced stimulation of
C/EBPβ activity was abolished in vitro in primary keratinocytes derived from C/EBPβ-
null mice and transfected with a mutant C/EBPβ where Thr188 (the mouse analog of
Thr235 in human) was mutated to Ala.
More recently Thr188 was described as a target for Cdk2 phosphorylation alongside
with a novel phosphoacceptor on Ser63 (Shuman et al., 2004). This does not exclude
MAPK from phosphorylating Thr188, as one site can be targeted by multiple kinases,
depending on the cellular context. Most coherently, phosphorylation of Ser63 and Thr188
by Cdks during specific stages of the cell cycle is reported to be essential for C/EBPβ to
facilitate oncogenic transformation by H-Ras.
Controversial findings were recently published on the phosphorylation of the serine-
rich region in the RD2 domain. Several researchers concur that some serines in this
region are targets for GSK3β (glycogen synthase kinase 3β) phosphorylation (Piwien-
Pilipuk et al., 2001; Tang et al., 2005; Zhao et al., 2005). However, if on one hand Tang
claims the phosphorylation to occur on Ser184 and Thr179, and that the event of
phosphorylation in adipocytes leads to acquisition of DNA-binding function, on the other
Zhao and colleagues show that Thr188 and Ser184 (and possibly Ser 180 and Ser176) are
the preferred targets for GSK3β  phosphorylation in resting osteoblasts and that
dephosphorylation will increase DNA-binding activity. It is hard to conceive that
different cellular contexts can explain such opposing effects. Perhaps the in vitro
procedures that have been used in these studies have produced some experimental
artifacts, which could be clarified with appropriate in vivo approaches.
C/EBPβ is known to be phosphorylated on several other residues outside of RD2.
Ser105 is a major phoshoacceptor for PKA in vitro, but this modification does not seem
to affect C/EBPβ’s DNA binding affinity, whereas phosphorylation of the same site by
PKC enhances C/EBPβ transactivation activity (Trautwein et al., 1993). PKA and PKC
are also able to phosphorylate Ser240 within the DNA binding-domain of C/EBPβ, this
time markedly impairing DNA recognition (Trautwein et al., 1994). In pituitary cells,
calcium-regulated phosphorylation of Ser276 within the leucine zipper domain of
C/EBPβ stimulates transcription from a Ca-calmodulin-dependent protein kinase II-
responsive element (Wegner et al., 1992). Activation of the p90 ribosomal S kinase
(RSK) results in the phosphorylation of rat C/EBPβ on Ser105 and of mouse C/EBPβ on
Thr217 and concomitantly stimulates proliferation in differentiated hepatocytes (Buck et
al., 1999). Moreover, phosphorylation by RSK on Thr217 allows C/EBPβ to associate
with procaspases 1 and 8, thereby inhibiting their processing and blocking the apoptotic
cascade. This suggests that C/EBPβ plays an important antiapoptotic role in the liver.
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Consistently, C/EBPβ-deficient mice display an enhanced programmed cell death in
hepatic stellate cells.
1.3 Goal of the Project
The task of a transcription factor can be widely diverse according to the cellular
context. C/EBPβ is expressed in a very broad range of tissues in the organism, and in
each tissue it has been described to have a relatively unique function. The targets of gene
expression for C/EBPβ can be entirely different from one cell type to another, or at
different stages of the cell cycle, or even dependent on environmental conditions. As
described above, the C/EBP transcription factors all share the same DNA-binding
consensus sequence. However, despite a certain redundancy, they all maintain distinct
functions. How can a molecule know what to do in each separate case? It could appear
simpler if Nature had devised a separate and different transcription factor for each
molecular requirement, highly specialized in one particular task. However, such a system
would be energetically unfavorable to the organism if we consider the amount of
additional genes, protein synthesis and metabolic organization that this would involve.
Evolutionarily, it is by far more convenient to use the same tools for different purposes
and to guide these tools through their tasks by an extremely accurate fine tuning. This is
why it is important for scientists to understand the regulation of a transcription factor,
both at the transcriptional and the posttranslational level.
In my thesis project I have endeavored to analyze the regulation of the C/EBPβ
transcription factor in the most physiological conditions possible. Indeed, to avoid
experimental artifacts due to protein overexpression, or the use of cell lines, or even to
the absence of a cellular context, I have, whenever possible, used in vivo experimental
models, such as the mouse. I have also addressed very specific questions about C/EBPβ
regulation, both at the transcriptional and the posttranslational level, with the help of
genetic engineering.
Shortly before and during the years of my PhD, several papers were published
suggesting that CREB regulates C/EBPβ transcription (Niehof et al., 1997; Berrier et al.,
1998; Bradley et al., 2003), and that it physically binds the C/EBPβ promoter during
adipogenesis (Zhang et al., 2003). In order to dissect the effects of CREB regulation, and
to understand when and where it is involved, I specifically deleted a short sequence on
the C/EBPβ promoter that carries the two CRE elements, and made a mouse line carrying
this deletion. The analysis of this mouse line is one of the main branches of my project.
The second part of my project focuses on some of the posttranslational modifications
that modulate C/EBPβ activity.  It is not difficult for a kinase to phosphorylate a protein
where it finds a consensus sequence if both kinase and protein are the most highly
represented molecules in the system, however this doesn’t prove that the same event
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takes place in physiological conditions. None of the numerous phosphorylations that have
been described for C/EBPβ have been proven genetically, although most of them have
been connected to a functional role. I have chosen to analyze the phosphorylation events
that take place in the RD2 domain of C/EBPβ, and to understand their physiological role
by mutating the phosphoacceptor sites to alanine. One site is the Thr188 phosphorylation
site, already described to be involved in oncogenic Ras transformation in the skin (Zhu et
al., 2002). In parallel, I also mutated three serines, shortly upstream from Thr188, some
of which have recently been described as GSK3β phosphorylation sites (Tang et al.,
2005; Zhao et al., 2005), but whose role still seems to be an open question. Once again
mouse lines were made from these mutants and analyzed attentively.
It is hardly feasible to study a transcription factor in every tissue that it is likely to be
expressed, particularly in the case of C/EBPβ for the reasons stated above. Furthermore,
in many tissues when one C/EBP family member has been knocked down, another
member, expressed at equally high levels, can take over the missing C/EBP and, at least
partially, mask the effects of its absence. In the case of C/EBPβ, C/EBPα very often has
given problems of redundancy. To ensure an accurate analysis, I chose to work on a
tissue where C/EBPα is absent, and where C/EBPβ is by far the predominant isoform,
that is the macrophages. By studying the transcriptional and posttranslational regulation
of C/EBPβ in the macrophages, I aim at finding novel downstream targets of C/EBPβ
transcription, and possibly learn more about the role of the transcription factor in the
immune system.
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2. MATERIALS AND METHODS
All the experiments in this thesis were carried out by myself, with the exception of
the first part of the cloning of the R26(ARIAD) targeting construct, which was done by
Elke Kurz. FACS analyses were done in collaboration with Peggy Kirstetter.
2.1 Molecular Biology
Standard protocols for molecular biology were taken from Molecular Cloning
Laboratory Manual (2nd edition). For DNA preparation: MiniPrep, QIAquick PCR
purification and Gel extraction kits (Qiagen) were used according to manufacturer
instructions. Ligations were performed using T4 DNA ligase from New England Biolabs.
Restriction enzymes were purchased from New England Biolabs. For cloning, E. coli
strain XL1-blue was used, except for pcDNAI plasmids, for which the MC1061/P3 strain
was used.
2.1.1 Plasmids
For testing the ARIAD system, the pL2N2-RHS3H/ZF3 plasmid (for simplicity it was
referred to as pL2N2(ARIAD) in the Results) was purchased with the ARGENT™
Regulated Transcription Retrovirus Kit (Version 2.0; ARIAD), and the ZFHD-GFP
plasmid, cloned by Elke Kurz, is a construct bearing the ZFHD motif followed by the IL2
promoter and then the GFP gene, on a pC4M-F2E expression plasmid backbone (from the
ARGENT™ Regulated Heterodimerization Kit, ARIAD). The dimerizer (AP21967) used
in this experiment is a chemically modified derivative of rapamycin and is also provided
by the ARIAD kit.
For stable expression of exogenous proteins, retroviral vectors were used. Wild type
C/EBPβ, as well as the T188A and 3S/A mutants were cloned in the pBabePuro plasmid
using the BamHI and EcoRI restriction sites. Infected cells were selected with 1µg/µl
puromycin until complete death of uninfected controls. For transient transfections, wild
type C/EBPβ and the T188A and 3S/A mutants were cloned into the pcDNAI expression
plasmid using BamHI and EcoRI. For Cyclin D1-HA and C/EBPα transient expression,
pCMV-cyclinD1-HA and pcDNA3-C/EBPα expression plasmids were kindly provided
by Dr Tetsuhiro Fujimoto and Dr Oksana Bereshchenko respectively.
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2.1.2 Targeting Constructs
The β∆CRE-neo targeting construct was obtained by cloning homology arms in the
pSVKeo-X1 targeting vector, inserting the ZFHD sequence next to the Neo cassette, and
knocking the resulting construct in the genomic clone of C/EBPβ. In detail, the 210bp
DNA stretch (nt -370 to –161, left arm) immediately upstream from the first CRE
element was cloned in the polycloning site of pSVKeo-X1 upstream of the Neo cassette
using the AscI and SalI restriction sites. The 127bp DNA stretch (nt -108 to +19, right
arm) immediately downstream of the second CRE element in the pSVKeo-X1
polycloning site was cloned downstream of the Neo cassette using the XhoI and NotI
restriction sites. A 79bp linker DNA encoding the ZFHD recognition element was
obtained by annealing complementary oligonucleotides carrying the ZFHD sequence, and
cloned between the lox P site and the right arm using the PacI and XhoI restriction sites.
This construct was inserted in the C/EBPβ genomic clone by ET recombination (Angrand
et al., 1999). The C/EBPβ genomic clone was obtained by bringing together a 2kb XbaI-
NotI fragment of the C/EBPβ promoter from the 9N1R plasmid (kindly provided by Dr.
E. Sterneck), to the NotI-BamHI fragment, which includes the coding sequence and 6kb
of the 3’ utr, coming from the 3N2∆B plasmid (also courtesy of Dr. E. Sterneck). The
backbone of this construct is pBluescript-KS.
For the construction of the R26(ARIAD) targeting vector, the EcoRI-BamHI
fragment, which includes transactivation domain (TAD), IRES and DNA binding domain
(DBD) on the ARIAD pL2N2-RHS3H/ZF3 vector, was cloned in a plasmid called
pR26SALPA, which is a pBS plasmid in which the splice acceptor and polyA site from
the original Rosa26 gene are cloned separated by a polylinker. Two homology arms from
the ARIAD pL2N2-RHS3H/ZF3 vector were cloned on either side of the floxed Neo
cassette in pSVKeo-X1. The left homology arm was a 289 DNA stretch corresponding to
the 3’ end of the TAD of the ARIAD transcription factor, and it was cloned upstream of
the pSVKeo-X1 Neo cassette using the KpnI and SalI restriction sites. The right
homology arm was a 336bp DNA stretch corresponding to the first half of the IRES
which immediately follows TAD on the ARIAD pL2N2-RHS3H/ZF3 vector, and it was
cloned downstream of the pSVKeo-X1 Neo cassette using the XhoI and SacII restriction
sites. The resulting construct was used to knock in the floxed Neo cassette between TAD
and the IRES in the pR26SALPA(ARIAD) vector by ET recombination. Finally, the 6kb
long fragment carrying all the ARIAD construct from pR26SALPA(ARIAD) was cloned
in the pR26-1 targeting construct (kindly provided by Dr. P. Soriano). This was achieved
with an intermediate passage in the pUC19 vector in which a DNA polylinker was cloned
between EcoRI and HindIII carrying the following restriction sites: NheI-AscI-PacI-SacI-
NheI. An AscI-SacI 6kb fragment was cut out of pR26SALPA(ARIAD) by partial
digestion and cloned in the polylinker. Then the fragment was cut out again with NheI
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and cloned into pR26-1 linearized with XbaI, since the NheI and XbaI restriction sites
have complementary overhangs.
The cloning strategy of the T188A and 3S/A mutants is extensively described in the
Results. The first cloning step was done in pGL3 (Promega), which has the BspEI
restriction site in its sequence. The first half of the C/EBPβ gene, generated as a BamHI-
BspEI fragment by PCR, using an antisense oligo which created the silent BspEI
restriction site in the C/EBPβ coding sequence, was cloned in pGL3. The fragment was
excised by a BamHI-XmaI digestion and cloned in pBS. Next, an XmaI-EcoRI fragment,
corresponding to the 3’ portion (from just before Thr188 to the stop codon) of the
C/EBPβ coding sequence was generated by PCR using a sense oligonucleotide that
inserted the XmaI site as silent mutation and, in the case of T188A, also the mutation of
the Thr188 to Ala. This fragment was inserted in the pBS construct with the BamHI-
BspEI C/EBPβ fragment. The resulting plasmid was opened with BspEI and XmaI, and
DNA linkers carrying the mentioned mutations were inserted. The mutations were
inserted in the targeting construct by subcloning the 380bp BstBI-PstI fragment from the
C/EBPβ coding sequence with the mutations into the NSRI plasmid, which carries a
NotI-SalI fragment of the genomic clone of C/EBPβ  with an ectopic EcoRI site just
before the start site. The NotI-SalI fragment was then transferred into the pTV-flox-
C/EBPβ targeting construct (NSRI and pTV-flox-C/EBPβ are a courtesy of Dr. A.
Leutz).
To improve the targeting efficiency of the pTV-flox-C/EBPβ phosphorylation
mutants, after linearizing the vector with a XbaI digestion, we annealed “DNA splinkers”
to the overhangs (Kalisch et al., 1986). The splinkers are oligonucleotides designed in a
way that permits their self-annealing so as to form hair pin loops with overhangs
complementary to those of the open targeting construct. This technique helps to avoid
that the single stranded overhangs insert unspecifically in the genomic DNA of the ES
cells.
2.2 ES Cells and Mouse Strains
2.2.1 ES Cell Transfection and Generation of Mouse Lines
E14.1 129/Ola ES cells were grown on mitomycin C-treated primary embryonic
fibroblasts at 37°C, 5% CO2 in Knockout DMEM with sodium pyruvate (Gibco),
supplemented with 15% serum replacement, 100U/ml penicillin, 100µg/ml streptomycin,
2mM glutamine, 1% non essential amino acids, 0.1 mM β-mercaptoethanol and
1000U/ml leukemia inhibitor factor (LIF). Cells (15 million) were electroporated in
800µl of phosphate-buffered saline (PBS) with 30µg of linearized targeting vector DNA
at 240V, 500µF for 6 msec in a Bio-Rad Gene Pulser. Cells were plated on gelatin-coated
10cm dishes and transferred 36 hr later to growth medium supplemented with G418
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(150µg/ml). G418-resistant colonies were picked 9 days later. Homologous
recombination was screened by genomic Southern blot hybridization.
For the generation of mutant mice, two ES cell clones derived from each construct
were injected into C57BL/6 blastocysts and implanted in foster mothers. The resulting
chimeras were bred for germline transmission. Agouti animals were genotyped, in order
to distinguish the heterozygous from wild-type animals, using Southern blot analysis.
Chimeras and the resulting mouse line were always crossed to C57BL/6 strains. Mice
were kept in a clean (SPF) facility, and sacrificed by CO2 asphyxiation.
2.2.2 Genotyping
For genotyping, genomic DNA was prepared from tails with the following protocol.
Tails were incubated overnight at 55°C in 700µl lysis buffer (50mM Tris, pH8, 100mM
EDTA, 100mM NaCl, 1% SDS, 0.5 mg/ml proteinase K). After incubation, 250µl of
saturated NaCl was added and samples were centrifuged (10 min 14000 rpm). The
supernatant was transferred to a new tube and 500µl isopropanol was added. The
precipitated DNA was centrifuged (10 min 14000 rpm) and washed in 70% EtOH. DNA
pellets were air dried and dissolved in 60µl TE buffer (10mM Tris pH8, 1mM EDTA).
β∆CRE mice were genotyped by PCR with primers designed to amplify the region
around the deletion (and ZFHD insertion) on the C/EBPβ promoter:
left primer: 5’-CGTGTAGCTGGAGGAACGAT-3’;
right primer: 5’-CGAGCGGGAGGTTTATAAGG-3’
producing a 363bp fragment for the wild type allele and a 420bp fragment for the mutant
allele. PCR reaction: 94°C 2 min, 34x(94°C 1 min, 58°C 1 min, 72°C 1 min), 72°C 5
min. The reactions were carried out with Promega Taq Polimerase as described by the
manufacturer, using 1µl DNA template and adding 5% DMSO.
R26(ARIAD) mice were genotyped by PCR as described by Soriano (1999) for R26
knock-in mice, except that the 3 primers were used 2 by 2 in two separate reactions.
3S/A and T188A mice were genotyped by Southern blot as described in the Results.
2.2.3 Southern Blotting
For screening of the ES cells, the confluent plates were washed with PBS. 50 µl of
lysis buffer (10mM Tris, pH 7.5; 10mM EDTA pH 8, 10mM NaCl, 0,5% sarcosyl,
100µg/ml proteinase K) was added to each well and incubated ON at 55°C. The DNA
was precipitated using 100µl EtOH/NaCl, washed three times with 70% ethanol, dried
and digested with EcoRI ON at 37°C. 18µl of the ES DNA preparation was separated
using 0.7% agarose gels, run at 30V for 15-18 hr. Before blotting, the gels were
depurinated for 15’ in 0.25M HCl, denaturated with 0.5M NaOH/1.5M NaCl, 2 times for
30 min, and finally neutralized with 0.5M Tris-HCl pH7.4/1.5M NaCl for 1 hr. Gels were
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blotted by capillary blotting overnight onto a GeneScreen Plus membrane (Perkin Elmer)
in presence of 20x SSC (3M NaCl, 0.3M C6H5Na3O7). The membrane was UV-
crosslinked with a UV Stratalinker (Stratagene), and baked at 65°C for 1 hr.
Prehybridization was performed in Quick-Hyb Buffer (Stratagene) for 2 hr at 65°C with
rotation. The probes were prepared using Random Primed DNA Labeling Kit (Roche)
and added to the membrane in Quick-Hyb buffer. For genotyping the β∆CRE, T188A
and 3S/A ES cells and mouse lines, the 700bp external probe used was obtained by an
EcoRI-XbaI digestion of the 9N1R plasmid. For counter-screening the T188A and 3S/A
ES cell clones, a second internal 500bp probe was obtained by a SphI-XmaI digestion of
the T188A construct.
Following hybridization, the blots were washed 3 times in 2x SSC/1% SDS and twice
in 0.2x SSC/1%SDS at 65°C with rotation. Hybridized probes were visualized using a
phosphoimager.
2.3 Cell culture
2.3.1 Cell Lines
J774 macrophages were grown at 37°C, 5% CO2 in RPMI (Gibco), 10% Fetal Bovine
Serum (FCS) (Gibco), 100U/ml penicillin, 100µg/ml streptomycin and 2mM Glutamine.
Q2bn quail fibroblasts, 293T cells and NIH3T3 murine fibroblasts were grown at
37°C, 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM)(Gibco) supplemented
with 10% FCS, 100U/ml penicillin, 100µg/ml streptomycin and 2mM Glutamine.
Transfection in Q2bn cells was performed by calcium phosphate coprecipitation, whereas
transfection in NIH3T3 cells was carried out with Lipofectamine Plus™  Reagent
(Invitrogen) as described by the manufacturer. Cells were grown to subconfluence before
splitting.
For inducing adipogenesis, NIH3T3 cells were infected in the presence of 20µg/ml
polybrene (Sigma) with a virus encoding either wild type C/EBPβ or the indicated
mutants. Cells were grown to confluence and then treated with 1µM dexamethasone
(Sigma) and 2µg/ml insulin in growth medium for 48hr. The cells were then shifted back
to plain growth medium until adipocytes appeared, around 3 days later. For Oil Red O
staining, the cells were washed two times in PBS and fixed in 4% paraformaldehyde/PBS
for 1 hr. Fixed cells were washed 3 times in PBS and stained with a filtered solution of
2.1g Oil Red O in 1.05 l of 57% isopropanol for 30 min. Cells were then washed in water
and photographed. To measure the degree of staining, cells were air dried overnight and
the dye was extracted with isopropanol (1ml per 6 cm dish) for 1 hr. Absorbance was
read at 510nm.
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2.3.2 Primary Macrophages
For the bone marrow-derived macrophages, femurs and tibias were collected from a
mouse and crushed in a mortar in the presence of 1% FCS/PBS and filtered through a
45µm cell strainer (BD Biosciences). Cells were washed and resuspended in
differentiation medium consisting of RPMI (Gibco), 20% FCS, 50µM β-
mercaptoethanol, 100U/ml penicillin, 100µg/ml streptomycin, 2mM Glutamine and
20ng/ml macrophage colony stimulating factor (MCSF)(Sigma). The cells were cultured
in differentiation medium for 6 days. Then MCSF was depleted and the cells were left in
growth medium (as above but without MCSF). For macrophage activation, cells were
treated  (or not treated) with 100U/ml IFNγ (PeproTech) in growth medium, with 5%
FCS, for 16 hr. Next, the cells were stimulated with 100U/ml IFNγ and 1µg/ml LPS from
E. coli (Sigma) for 4 hr and then RNA or protein was extracted.
For the preparation of peritoneal macrophages, mice were killed 3 days after an
intraperitoneal injection of 1ml 3% thioglycollate broth (Sigma). Exudate cells were
harvested by washing the peritoneal cavity with 12ml PBS, washed and cultured in
DMEM, 5% FCS, 100U/ml penicillin, 100µg/ml streptomycin and 2mM Glutamine.
2.4 Gene Expression
2.4.1 Affymetrix
Total macrophage RNA was prepared using Trizol (Sigma) as specified by the
manufacturer. RNA was analyzed at the RH Microarray Center (Copenhagen University
Hospital, Denmark) using Affymetrix Mouse Genome U74A GeneChip™. Data analysis
was performed using Genespring software.
2.4.2 RT-PCR
First strand cDNA was synthesized from 1µg total RNA (prepared from tissues and
macrophages with Trizol) using Ready-To-Go T-primed first strand kit (Amersham
Bioscience). Relative mRNA levels were determined by real time PCR on a DNA Engine
(MJ Research) using DyNAmo SYBR green qPCR kit (Finnzymes).
The same PCR program was used for all the RT-PCR analyses, except that the
annealing temperature was adapted to each case (the annealing temperature is specified in
table 2.1 next to each primer pair): 95°C 3 min, 40 cycles of (94°C 10 sec, Tanneal 20 sec,
72°C 10 sec). The product content of the reactions was read after each PCR cycle. The
identity of specific products was confirmed by a melting curve analysis.
RT-PCR primers were constructed using Primer 3 software (MIT,
http://frodo.wi.mit.edu/primer3/primer3_code.html). cDNA sequence information was
retrieved at the ENSEMBL data base (EBI, www.ensembl.org). A total reaction volume
of 20µl was used: 5µl cDNA, 5µl of primer pair stock solution (1.2µM each) and 10µl
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DyNAmo SYBR green qPCR kit (Finnzymes) according to the manufacturer. mRNA
levels of each sample was evaluated in triplicates and dilutions of control cDNA were
used to construct a standard curve. All cDNA levels were normalized to the level of
ubiquitin cDNA. RT-PCR primers are listed in table 2.1.
Table 2.1 RT-PCR primer list
Name Left primer Right primer Tanneal
C/EBPβ GGAGACGCAGCACAAGGT AGCTGCTTGAACAAGTTCCG 60°C
Msr1 CTGGACAAACTGGTCCACCT TCCCCTTCTCTCCCTTTTGT 58°C
Arginase 1 AACACGGCAGTGGCTTTAAC GAGGAGAAGGCGTTTGCTTA 57°C
IL13α1 CAGCTGGGATACAGGCATCT TGGTTTCCACAGCATTTCAA 58°C
Ccl8 GGGTGCTGAAAAGCTACGAG TTCCAGCTTTGGCTGTCTCT 58°C
Ccl20 AGAAAATCTGTGTGCGCTGA AGGTCTGTGCAGTGATGTGC 60°C
CD36 TCCCTCACTGGAGGAAACTG TGTGATATCTGGCCTTGCTG 58°C
CD38 CGAAGGAGCTTCCAGTAACG AGCTTTCCACCAGTGTTGCT 58°C
C-type lectin TCTGACAGAGGCCGTTCTTT CCACCTGGACCCTCTTACAA 57°C
IL2β GACTGAATGCAGCCTGTTGA GGTCCCCAAAGCAACATAGA 58°C
IL6 TCCTTCCTACCCCAATTTCC ACCACAGTGAGGAATGTCCA 58°C
IL10 CCAGGGAGATCCTTTGATGA CATTCCCAGAGGAATTGCAT 57°C
MARCO GGAACATCTGGCTGGACAAT GATTTCCATGTGGGTGGAAC 58°C
metallothionein ACCTCCTGCAAGAAGAGCTG GCTGGGTTGGTCCGATACTA 58°C
Mrc1 CCAGGAACAAGTGACACGAA AAGGACAAACCAATGCAACC 57°C
Procollagen 1α1 CAGTCGCTTCACCTACAGCA GGTGGAGGGAGTTTACACGA 58°C
Procollagen 1α2 CCGTGCTTCTCAGAACATCA GAGCAGCCATCGACTAGGAC 57°C
Procollagen 3α1 AAGGCTGAAGGAAACAGCAA TGGGGTTTCAGAGAGTTTGG 58°C
Procollagen 5α1 GGCGGGACAGTATTTGAAGA ATTTGGCCTCTGAGTGGATG 58°C
Procollagen 5α2 CAGCCAGTGTTCCACGTAAA TCTGCGAGGCTTCTTTTGAT 57°C
Procollagen 6α1 GGAGACCCCTCCTCTTCATC TTGAGGGAGAAAGCTCTGGA 57°C
Procollagen 6α2 ATCGTACACGCCATCAACAA CTGTCACCCAGGCTGATCTT 57°C
Procollagen C-pep CAAAGCAGTACAAGCGGTCA GCAGGGCACATACAACTTCA 60°C
TIMP 1 ATTCAAGGCTGTGGGAAATG CTCAGAGTACGCCAGGGAAC 57°C
TIMP 2 GCTGTCCCAAGGACACAAAT CTGAGGGGGAGTCCTTAACC 57°C
TIMP 3 AGCTGGCAAAGGCTTAAACA CAAGCTTCCAGCCAAACTTC 57°C
Ubiquitin GATCCTCTTACCCCCTCGTC CCTTTAGGCCACTCCTTCCT 58°C
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2.5 Immunohistochemistry and Biochemistry
2.5.1 FACS Analysis
The bone marrow-derived macrophage population was stained in wells of a 96 well
plate at 1.25x10(6) cells per sample. Cells were blocked with CD16/32 (an antibody
against Fcγ receptors) (BD Pharmingen) in PBS/1%FCS for 5 min on ice. Then the cells
were washed with PBS/1%FCS, centrifuged (2 min, 1200 rpm at 4°C), and stained with
APC-conjugated CD45, Mac1, F4/80, Gr1, B220, CD4, CD8 and Ter119 antibodies (all
from BD Pharmingen) in PBS/1%FCS for 15 min on ice in the dark. Finally, the cells
were washed twice in PBS/1%FCS. Labeled cells were analyzed on a FACS Calibur (BD
Biosciences). Data was analyzed using FlowJo software (Treestar).
2.5.2 Protein Extraction, SDS-PAGE, Anderson-PAGE and Western Blotting
For extracting proteins from mouse tissues, tissues were collected and snap frozen in
liquid Nitrogen. Next, they were crushed in a mortar while still frozen and the powder
was resuspended in lysis buffer (50mM Hepes, pH7.4, 10mM EDTA, 1% Triton X100,
10mM sodium orthovanadate, 50mM sodium pyrophosphate, 100mM sodium fluoride
and 1 Complete Mini Protease Inhibitor tablet/50ml solution (Boerinhger). If lumps
remained, the tissue was homogenized with an electric homogenizer. Whole cell protein
extracts from cultured cells were obtained by resuspending the cells in RIPA buffer
(150mM NaCl, 50mM Hepes, pH7.9, 0.1% SDS, 1% NP40, 0.5% sodium deoxycholate
and 1 Complete Mini Protease Inhibitor tablet/50ml solution). Phosphatase inhibitors
were added when necessary.
The extracts were cleared by centrifugation (10 min at 14000 rpm), and protein
concentrations were determined using the Bio-Rad Dc protein assay (Biorad). 2x SDS
loading buffer was added (100mM Tris pH6.8, 4%SDS, 20% glycerol, 0.2%
bromophenol blue and 3% β-mercaptoethanol). The protein extracts were resolved on
0.75mm thick minigels (Bio-Rad apparatus) by  SDS-PAGE. The resolving gel contained
15% acrylamide (Bio-Rad, stock solution 30% Acrylamide/bis-acrylamide 37.5:1 ratio),
375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% ammonium persulfate and 0.001%
N,N,N’,N’-tetramethylenediamine (TEMED)(BioRad). The stacking gel contained 4%
acrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% ammonium persulphate and
0.001% TEMED. The gels were run in Laemmli running buffer (25 mM Tris base, 200
mM glycine, 0.1% SDS) at a 100V. Proteins were transferred onto Protran nitrocellulose
(Schleicher & Schuell) using a Hoefer SemiPhor apparatus for 1 hr at a constant mA
(1mA/cm2 gel area) in transfer buffer (20 mM Tris base, 150 mM glycine, 0.1% SDS,
20% methanol).
Anderson-PAGE (Nebreda et al., 1995) is an SDS-free PAGE with a different ratio of
acrylamide to bis-acrylamide, which is able to separate proteins according to their charge
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as well as their molecular weight, and therefore it is used to discriminate phosphorylated
and unphosphorylated forms of the same protein. 15% resolving gels (30% acrylamide to
1% bis-acrylamide ratio = 174:1, 370mM Tris-HCl pH8.8) and 5% stacking gels (5%
acrylamide, 0.13% bis-acrylamide, 125mM Tris-HCl pH6.8) were used. Large gels were
poured (20cm long) and the protein extracts in SDS loading buffer were resolved at 100V
for 20 hr in Laemmli buffer.
Western blots were blocked in 5% milk in TBS-T (0.1M Tris-HCl pH7.5, 150mM
NaCl, 0.1% Tween-20 (BioRad)) for 1 hr at room temperature, and incubated with the
indicated primary antibodies 1 hr at room temperature, or overnight at 4°C (in the case of
the phospho-C/EBPβ(Thr235) antibody). Membranes were washed in TBS-T 3 times for
10 min before and after incubation with the secondary antibody against rabbit or mouse
IgG (Jackson Immunolaboratories, 1:10000). Horseradish peroxidase conjugated
secondary antibodies were used and ECL (Amersham Biosciences) revealed the signal.
For detecting C/EBPβ on Western blots α-C/EBPβ C19 antibody sc-150X (Santa
Cruz Biotechnology, 1:1000) was used for most experiments. Where specified, the α-
C/EBPβ ∆198 antibody sc-746 (Santa Cruz Biotechnology, 1:1000) was used instead. For
detecting the phosphorylation on Thr188 of the C/EBPβ  protein, a phospho-
C/EBPβ(Thr235) Antibody (Cell Signaling Technology, 1:1000) was used. For detecting
the HA-tagged Cyclin D1 we used an anti-HA antibody (Santa Cruz Biotechnology,
1:10000).
2.5.3 Chromatin Immunoprecipitation
J774 macrophages were grown to subconfluence in 10cm dishes. Cells were treated
or not treated with 1µg/ml LPS for 15 min. Next, cells were crosslinked with 1%
formaldehyde in the culture media for 10 min. Crosslinking was quenched by adding
0.125M glycin to the medium and incubating 10 min. Cells were then washed and
scraped in cold PBS. Finally, the cells were pelleted and resuspended in ChIP lysis buffer
(50mM Tris-HCl pH8, 10mM EDTA, 1% SDS) in a volume of 200µl/million cells. Cell
lysates were incubated on ice for 10 min. Chromatin was sheared by sonication (4 bursts
of 10 sec using a Sonoplus GM 200 sonicator (Bandelin Electronics), probe 72 at 20%
output). After sonication, lysates were centrifuged 10 min at 4°C to eliminate the cellular
debris. 200µl of the lysate was diluted 10 times in ChIP dilution buffer (16.7mM Tris-
HCl pH8, 167mM NaCl, 1.2mM EDTA, 1.1% Triton X-100 and 0.01% SDS) and cleared
by incubation with 30µl protein A beads (Amersham, 50% in ChIP dilution buffer) for 1
hr at 4°C with rotation. 4µg of anti-CREB antibody (Upstate) or unspecific rabbit IgG
(Santa Cruz Biotechnology) were added and lysates were incubated 16 hr at 4°C on
rotation. 30µl of a 50% Protein A bead solution was added, and the lysates were
incubated 4 hr at 4°C on a rotating wheel. Beads were collected by centrifugation and
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washed in ChIP dilution buffer, ChIP dilution buffer with 500mM NaCl, and twice in TE
(10mM Tris-HCl pH8, 1mM EDTA). Finally, the beads were resuspended in 100µl TE
and decrosslinked at 65°C in the presence of 1ng RNase for 4 hr. 50ng Proteinase K and
SDS to 0.5% were added, and the samples were incubated 1 hr at 42°C. DNA was
collected using Qiaquick gel extraction kit (Qiagen) according to the instructions of the
manufacturer. Precipitated DNA was analyzed by PCR using the following conditions:
94°C 2 min, 30 x (94°C 1 min, Tanneal 1 min, 72°C 1 min), 72°C 5 min. The annealing
temperature was 58°C for C/EBPβ promoter primer pair, and 60°C for the control The
reactions were carried out with Promega Taq Polimerase as described by the
manufacturer, using 2µl DNA template and adding 5% DMSO. The PCR products were
analyzed by electrophoresis on a 2% agarose gel.
The ChIP primers were constructed using Primer 3 software (MIT,
http://frodo.wi.mit.edu/primer3/primer3_code.html), based on sequence information
retrieved from the ENSEMBL data base (EBI, www.ensembl.org). The primers used
were specific for a 140bp region on the C/EBPβ promoter that includes the CRE
elements. As an unspecific control, we used primers that amplified a 200bp DNA stretch
on the C/EBPβ  3’ utr, about 1.5kb downstream of the C/EBPβ coding sequence. The
primers are the following:
β promoter left: 5’- CACTCCCCGCCGCGCCCTCTC -3’
β promoter right: 5’- CGAGCGGGAGGTTTATAAGG-3’
β 3’ utr left: 5’- CGTTCTGCAAGCCCTGGG-3’
β 3’ utr right: 5’- GAGTCGCTGGTCACCCCT-3’
2.5.4 Coimmunoprecipitation
For detection of protein-protein interactions in transiently transfected cells, 293T cells
were transfected with 4µg DNA in total of pCMV-HA-tagged cyclin D1 and pcDNA1-
C/EBPβ or the specified mutants, or pcDNA3-C/EBPα as negative control, using the
calcium phosphate precipitation method. 40 hr after transfection, cells were washed and
harvested in cold PBS. Whole cell extracts were prepared in CoIP lysis buffer (50mM
Tris-HCl pH8, 150mM NaCl, 1mM EDTA, 0.5% NP40, 1mM DTT, and 1 Complete
Mini Protease Inhibitor tablet/50ml solution (Boerinhger)). The lysates were precleared
with 20µl Protein A beads (50% suspension in CoIP lysis buffer) at 4°C for 1 hr. Cleared
lysates were incubated with 2µg C19 α-C/EBPβ (Santa Cruz Biotechnologies) for 3 hr at
4°C with rotation, and protein complexes were precipitated on 20µl 50% Protein A beads
after a 1 hr incubation (4°C with rotation) of the samples with the beads. Immobilized
complexes were washed 4 times with CoIP lysis buffer and finally decrosslinked by
suspension in 2x SDS loading buffer (100mM Tris pH6.8, 4%SDS, 20% glycerol, 0.2%
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bromophenol blue and 3% β-mercaptoethanol) and incubation at 98°C for 5 min.
Samples were analyzed by Western blotting as described above.
2.6 In Vitro Assays
2.6.1 NO Assay
The NO assay was performed on peritoneal macrophages. Cells were plated in
triplicates on a 96 well plate at 0.1 million cells/well. The cells were either left untreated,
or treated with 10U/ml IFNγ and /or 10ng/ml LPS for 48 hr. NO2 anion concentration in
the medium was measured with the Greiss reagents (Ding et al., 1988). To make the
measurements more accurate and comparable from mouse to mouse, the NO
concentrations were normalized to the degree of Thiazolyl blue (MTT) (Sigma) vital dye
staining. Briefly, 20µl of a 1.25mg/ml MTT in culture medium solution was added to the
well in which the cells were already in 100µl medium. Cells were incubated with the dye
for 1 hr at 37°C. 60µl of medium was removed from each well, and then the cells were
lysed with 140µl cold acidic isopropanol (isopropanol + 0.24% HCl). Absorbance was
read at 570nm.
2.6.2 Reporter Gene Assays
Q2bn cells were plated at 3x10(5) cells/60mm dish and transfected by calcium
phosphate coprecipitation with 200ng pcDNAI-C/EBPβ or the indicated mutants, 0.5µg
pMim1∆-Luc and 1µg pRSV-βgal. After 48 hr, cells were washed with PBS, and
harvested by addition of 1ml TEN (40mM Tris-HCl pH7.5, 1mM EDTA pH8, 150mM
NaCl) per dish. Cells were pelletted, washed in PBS and finally lysed with 100µl
Reporter Gene Assay Lysis Buffer (100 mM potassium phosphate, pH7.8, 0.2% Triton
X-100, 1 mM DTT). The cell debris was removed by centrifugation, and the lysate was
used in either a luciferase or β-gal assay. Relative luciferase units were defined as β-gal
normalized luciferase activity.
The luciferase activity was measured using a Lumat LB 9507 luminometer. The
samples were measured using 50 µl lysate in 350 µl reaction solution (25 mM Gly-Gly
pH 7.8, 2 mM ATP, 10 mM MgSO4). 100 µl injection solution (25 mM Gly-Gly pH7.8,
0.2 mM Luciferin) was injected in each reaction.
The β-gal activity was measured as follows: 0.4ml ONPG (20mg/ml in ethanol) and
1.4µl MeSH was added to 10ml of the β-gal buffer (60mM Na2HPO4, 40mM NaH2PO4,
10mM KCl, 1mM MgCl2). 50µl lysate was placed in a well on a 96 well plate and 150µl
β-gal buffer was added and incubated at 37oC. The reaction was stopped with 50µl 1M
Na2CO3 and the absorbance was measured at 414nm in an ELISA-reader.
For luciferase assays on NIH3T3 cells, the Dual Luciferase Assay Kit (Promega) was
used. Subconfluent cells on 60mm dishes were transfected using the Lipofectamine
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Plus™ Reagent (Invitrogen) with 200ng pcDNAI-C/EBPβ or the indicated mutants,
800ng pMim1-∆Luc reporter and 2ng pRL-SV40 (the Renilla luciferase reporter). The
assay was carried out according to the manufacturer’s intructions, and read on a Lumat
LB 9507 luminometer.
RESULTS
38
3. RESULTS
3.1 Generation of the β∆CRE Mouse Line
In order to understand the role of CREB in regulating C/EBPβ transcription, a mouse
line was generated, in which the 52bp DNA segment carrying the two CRE elements (i.e.
the TGACG motifs at –161 and –113 from the start site) on the C/EBPβ promoter were
deleted. The deletion does not include the TATA box, which is situated at –86bp from the
start site, however it slightly overlaps with a putative C/EBP recognition motif, because
the T of the CRE element at –161 coincides with the T of the CAAT motif for C/EBP
binding. In the site of deletion we inserted a DNA segment carrying a recognition motif
for an artificial transcription factor commercialized by ARIAD. This was done in the
future prospective of being able to artificially induce the expression of the C/EBPβ gene,
and to reverse any phenotype obtained from the loss of CREB regulation. The cis
recognition motif is called ZFHD, and its use will be described further on in this thesis.
To enable selection of ES cells, a floxed Neo cassette was also inserted at the point of
deletion, immediately upstream from the ZFHD. The engineered promoter was inserted
into a plasmid carrying the genomic clone of C/EBPβ by ET recombination (figure
3.1A).
The resulting construct, which is the targeting vector, was checked by sequencing
(not shown) and by transformation in the XL1-Cre bacterial strain, to ensure that a
correct recombination and excision of the Neo cassette could be obtained (not shown).
The targeting construct was linearized by cutting in the ScaI site inside the AmpR gene
and transfected into ES cells. ES cell clones were selected with G418 and screened by
Southern blot as shown on figure 3.1B. Positive clones (figure 3.1C) were injected in
blastocysts and chimeric mice were obtained.
Once germline transmission of the deletion was achieved, the β∆CRE-neo mice were
crossed to a deleter-Cre line, in order to eliminate the Neo cassette inside the C/EBPβ
promoter by Cre recombination. The resulting line, called β∆CRE, is characterized by the
substitution of the CRE elements in the C/EBPβ promoter with the ZFHD motif (figure
3.1D). The β∆CRE line is genotyped by PCR (see Materials and Methods). For
simplicity, from here on the β∆CRE mutant allele will be referred to as DC.
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A.
B.
      C.              D.
Figure 3.1: Schematic representation of the targeting strategy. A. Left and right homology
arms flanking the CRE elements on the C/EBPβ promoter were cloned in the pSVKeo-X1 vector
on the two sides of the Neo cassette followed by the ZFHD. After ET recombination in the
genomic clone, the resulting vector was used to target the wild type allele (B.). ES cells were
screened with the EcoRI-XbaI probe, external to the targeting construct, on EcoRI-digested
genomic DNA. The lengths of the wild type and targeted allele digested fragments are indicated.
C. The wt allele is 4.6 Kb long (lower band), whereas the mutant allele gives a band of 6.4 Kb
(upper band on fifth lane). D. Schematic representation of the β∆CRE allele.
3.1.1 β∆CRE DC/DC Females Are Fertile
One of the most striking phenotypes of the C/EBPβ knock out mouse is the female
sterility due to an impairment in the maturation of the granulosa cells in the ovaries
(Sterneck et al., 1997). In order to check the fertility of the β∆CRE homozygous
(DC/DC) females, we set up matings between four DC/DC females and four DC/+ males.
pSVKeoX1-A-B-ZFHD
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Four DC/+ females were used as controls inside the same cage as the mutants.  After 30
days of mating, 3 out of 4 controls were pregnant or had delivered, and two out of four
DC/DC females were pregnant, and eventually delivered normal litters. Moreover, as was
mentioned in the introduction, mice deficient for C/EBPβ , display impaired
lobuloalveolar development of the mammary gland, which is associated with perturbed
proliferation of mammary epithelial cells in the early phase of pregnancy (Seagroves et
al., 1998). For this reason, we observed whether the DC/DC females had a problem in
lactation. However, the DC/DC mothers were able to lactate, and the pups grew and were
weaned at the same stage as litters born from control females. We can therefore conclude
that β∆CRE homozygous mice do not display defects in female reproduction.
3.1.2 C/EBPβ Expression in β∆CRE Tissues
To have a general view of the level of expression of C/EBPβ in mice carrying a
deletion in  the promoter of this gene, we extracted RNA from several tissues where the
transcription factor is known to be present and performed RT-PCR analysis for C/EBPβ.
Tissue from C/EBPβ knockout mice was used as a negative control. In the liver, the
levels of C/EBPβ mRNA are quite comparable between DC/DC and wild type mice
(Figure 3.2A). In the fat there seems to be a stronger expression of C/EBPβ in the DC/DC
(Figure 3.2B). In the brain, C/EBPβ was shown to be implicated in synaptic plasticity and
memory consolidation (Alberini et al., 1994). Taubenfeld and coworkers have suggested
that CREB is involved in regulating C/EBPβ expression in the pathway that leads to
hippocampal learning (Taubenfeld et al., 2001). In detail, they observed a correlation
between CREB activation and subsequent C/EBPβ  upregulation following a spatial
learning task. We therefore checked the levels of C/EBPβ  mRNA in the hippocampus,
and found them to be comparable to the wild type controls (Figure 3.2C). However, this
is not too surprising considering the fact that the mice had not been made to perform a
learning task before being sacrificed. The fact that C/EBPβ expression is somewhat
higher in the DC/DC fat, could possibly be explained by the partial deletion of the C/EBP
binding site on the C/EBPβ promoter due to its partial overlap with the CRE element.
This would mean that C/EBPβ participates in an autoregulatory feedback loop, thereby
restricting its own transcription when already present at high levels. We have further
support of this theory from some data obtained with an affymetrix that will not be part of
this thesis. Briefly, an affymetrix was carried out on NIH3T3 fibroblasts transduced
either with C/EBPβ or with empty vector. A microarray is capable of detecting only the
endogenous transcript, because the ESTs for the screening are chosen from the 3’utr of
the gene, which is absent in an expression vector.
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A.                 B.
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Therefore, we were able to monitor C/EBPβ endogenous expression in the presence of
the exogenous protein. Indeed, we observed that the endogenous levels of C/EBPβ were
consistently low compared to the empty vector-transduced cells (figure 3.3).
C/EBPβ is involved in adipogenesis, although the C/EBPβ knockout mouse doesn’t
present gross defects in the white adipose tissue (Tanaka et al., 1997). To check whether
the higher expression of C/EBPβ in DC/DC fat could perturb its morphology, we
weighed the epidydimal fat pads of β∆CRE mice and normalized the values to the total
body weight of each mouse. Predictably, there was no difference between DC/DC mice
Figure 3.2: Relative C/EBPβ  mRNA
levels in β∆CRE tissues.
Expression in the liver (A), the fat pads
(B), and the hippocampus (C). The signal
obtained in the knockout sample (ko)
should be considered background noise.
n=2.
Figure 3.3: Expression levels of endogenous
C/EBPβ in cells overexpressing exogenous
C/EBPβ. Affymetrix on NIH3T3 fibroblasts
transduced either with wild type C/EBPβ or with
empty vector (pBP).
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and their wild type littermates (not shown). Moreover, we made histological sections of
the fat pads and stained the adipose tissue with eosin-hematoxilin. Once again there was
no evident difference between mutant and wild type (data not shown).
3.1.3 CREB Physically Binds the C/EBPβ Promoter in Macrophages upon LPS
Stimulation
Experiments conducted on the J774 macrophage cell line showed that the stimulation
of the cells with LPS correlated with the phosphorylation of CREB, and therefore its
activation, after 10 minutes of treatment, and the upregulation of C/EBPβ after four hours
(Bradley et al., 2003).
To exclude the possibility that the upregulation of C/EBPβ following CREB
phosphorylation could be a secondary, and not direct, effect in the signaling cascade, we
checked whether CREB could be immunoprecipitated on chromatin bound to the C/EBPβ
promoter. The ChIP experiment was performed on J774 macrophages in which protein-
DNA interactions were crosslinked after a 15 minute LPS treatment. As shown in figure
3.4, CREB was immunoprecipitated on the C/EBPβ promoter only in the LPS-treated
cells. The PCR that was used for this experiment is specific for a 140bp DNA fragment
that covers the CRE elements on the C/EBPβ promoter.
         __β promoter               _  3’UTR (control)__  PCR
          1    2    3    4     5    6    1    2    3    4     5    6
Figure 3.4: ChIP on J774 macrophages. J774 macrophages were treated (lanes 4-6) or not
treated (lanes 1-3) with 1µg/ml LPS for 15 minutes. The PCR shows that CREB binds onto the
C/EBPβ promoter only after LPS treatment (compare lanes 3 and 6 of β promoter PCR). The
amplification of a DNA fragment ca 2kb downstream from the CRE elements (in the 3’ utr of the
C/EBPβ gene) was used as a control PCR.
These results suggested an interesting model to use for analyzing the β∆CRE
mice. We decided to check whether the upregulation of C/EBPβ following LPS
stimulation was dependent on CREB activation in primary macrophages as well.
1. input                  4. input/LPS
2. IgG                    5. IgG/LPS
3. α-CREB            6. α-CREB/LPS
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3.1.4 IFNγ/LPS-Dependent Induction of C/EBPβ Expression Requires the CRE
Elements on the C/EBPβ Promoter
Next, we tried to set up the best conditions for analyzing the β∆CRE primary
macrophages. To find the time point with the strongest induction of C/EBPβ after LPS
stimulation, we performed a time course in which primary macrophages of wild type
mice were treated with LPS for 2-4-6-8 and 24 hours before RNA extraction. The RNA
was reverse-transcribed and C/EBPβ expression levels were measured by real time PCR.
Albeit a certain variability, the strongest induction took place between two and four hours
(data not shown), with a smaller standard deviation at four hours. We found that an
overnight pre-treatment with IFNγ, with the aim of priming the macrophages, reduced the
variability significantly. For future experiments, we chose to prime the macrophages with
IFNγ and to stimulate with IFNγ and LPS for four hours.
β∆CRE primary macrophages were obtained from bone marrow cultures in the
presence of M-CSF (see Materials and Methods). To make sure that our macrophage
population was relatively pure, we stained the wild type cells with conjugated antibodies
against specific markers for the major components of the hematopoietic system and
analyzed them by FACS. The primary cells were very high in Mac-1 and F4/80 (figure
3.5A and B respectively), typical macrophage markers, and showed a significant level
(43%) of Gr-1 (figure 3.5C). Gr-1 is considered a granulocyte specific marker, however a
certain class of macrophages, termed natural suppressor (NS) cells, originates from
granulocyte-monocyte progenitors, and express Gr-1, Mac-1 and F4/80 as surface
markers (Atochina et al., 2001). B lymphocytes, detected with B220 and CD-19 (figure
3.4D), and T lymphocytes, detected with CD-4 and CD-8 (figure 3.5E), were practically
absent, as were the erythrocytes, marked by Ter-119. We therefore considered our
population to be sufficiently pure to proceed with our studies.
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Figure 3.5: FACS analysis of cultivated bone marrow-derived macrophages. Bone marrow cells from
wt mice were cultured for 6 days in the presence of M-CSF and stained with antibodies specific for
macrophages (A and B), granulocytes (C), B-lymphocytes (D), T-lymphocytes (E) and erythrocytes (F).
The gate was set on CD45 (a marker for all bone marrow-derived cells) positive cells.
DC/DC and wild type primary macrophages were treated overnight with 100ng/ml
IFNγ and the following morning 1µg/ml LPS was added to the culture and incubated for
4 hours. RNA was extracted from the cells and C/EBPβ expression levels were
determined by RT-PCR. As shown in figure 3.6, IFNγ/LPS stimulation induced a 3 fold
upregulation of C/EBPβ, whereas this was not the case for the DC/DC macrophages.
This experiment clearly indicates that the CRE elements on the C/EBPβ promoter are
necessary for IFNγ/LPS-dependent induction of C/EBPβ in primary macrophages. This
information is new, as the CREB-dependence of C/EBPβ  activation is not only a
correlation, but a proof in vivo in macrophages.
Figure 3.6: C/EBPβ expression
following IFNγ/LPS stimulation.
The experiment was repeated
several times with similar results.
n=6. The difference between
wt+IFN/LPS and DC/DC+IFN/LPS
is significant as indicated by
Student’s t test [t(*)=0.01].
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3.1.5 Affymetrix Analysis on IFNγ/LPS-Stimulated β∆CRE Macrophages
The experiment described above turned out to be a very useful tool to find novel
downstream targets for C/EBPβ following IFNγ/LPS-stimulation. We performed an
Affymetrix DNA micro-array analysis on total macrophage RNA of DC/DC+IFNγ/LPS
samples, from two different mice, and two wt+IFNγ/LPS controls. In Table 3.1 are
reported the genes resulted from the data analysis that we considered most pertinent to
this study and that presented a fold regulation of at least 2.
Affy ID Gene description Fold regulation
Downregulated in DC/DC
1452250_a_at procollagen, type VI, alpha 2 46.54
1419549_at arginase 1, liver 31.32
1422437_at procollagen, type V, alpha 2 25.10
1427883_a_at procollagen, type III, alpha 1 23.93
1423669_at procollagen, type I, alpha 1 19.14
1450857_a_at procollagen, type I, alpha 2 17.46
1437165_a_at procollagen C-proteinase enhancer protein 15.90
1416740_at procollagen, type V, alpha 1 14.52
1448590_at procollagen, type VI, alpha 1 9.70
1449334_at tissue inhibitor of metalloproteinase 3 7.81
1460227_at tissue inhibitor of metalloproteinase 1 7.64
1457871_at macrophage bacteria-binding receptor MARCO 7.11
1454677_at tissue inhibitor of metalloproteinase 2 4.72
1428942_at metallothionein 2 3.65
1450430_at mannose receptor, C type 1 3.15
1425435_at Macrophage scavenger receptor type 1 3.11
1425951_a_at C-type lectin, superfamily member 10 3.06
1421239_at Interleukin 6 signal transducer 2.94
1450136_at CD38 antigen 2.78
1419684_at small inducible cytokine A8 (Ccl8) 2.69
1450883_a_at CD36 antigen 2.07
1422029_at Ccl20 2.06
1454783_at Interleukin 13 receptor, alpha 1 2.04
1448759_at Interleukin 2 receptor, beta chain 2.02
Upregulated in DC/DC
1450330_at Interleukin 10 3.24
.Table 3.1: Affymetrix data analysis on wt+IFNγ/LPS versus DC/DC+IFNγ/LPS macrophage
total RNA. n=2. The normalized values of samples with the same genotype were averaged and
used to calculate the fold regulation.
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All the genes listed in table 2 were counterchecked by RT-PCR using primary
macrophages from new DC/DC and wild type mice. Three of the genes were reconfirmed
and these are arginase 1, macrophage scavenger receptor 1 (Msr1), and interleukin 13
receptor α1 (IL-13α1)(figure 3.7A, B, C). All the other genes were not confirmed by RT-
PCR.
  A.                      B.
  C.
3.1.6 β∆CRE Mice Display an Enhanced NO Production in Response to LPS
Treatment
As a preliminary characterization of the functionality of the β∆CRE macrophages, we
decided to check the release of nitric oxide (NO) of the cells in response to LPS and/or
IFNγ. Thioglycollate-elicited peritoneal macrophages were plated at low density in a 96-
well dish and treated for 48h with LPS and/or IFNγ. NO release in the culture medium
was determined with the Greiss reagents (see Materials and Methods). When the
macrophages are treated with LPS and IFNγ together, DC/DC and wild type cells display
a very similar NO release. However, when the macrophages are treated with the reagents
individually, the DC/DC cells react by releasing more NO than the wild type. The result
is not significant in the IFNγ treated samples, due to a high standard deviation, but it is
significant in the LPS-treated samples (t=0.004) (figure 3.8).
Figure 3.7: Real time PCR analysis of
C/EBPβ dependent genes.
A. Arginase 1 t(*)=0.008; B. Macrophage
scavenger receptor 1 t(*)=0.038; C.
Interleukin 13 receptor α1 t(*)=0.015.
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3.2 Preliminary Studies on the ARIAD Transcription Factor
As mentioned in the first paragraph of this section, we would like to use an artificial
transcription factor to switch on C/EBPβ transcription in the β∆CRE mouse in a tightly
regulated conditional manner. We chose to use the ARGENT™ Regulated Transcription
Retrovirus Kit commercialized by ARIAD. The kit provides retroviral vectors encoding a
transcription factor that is expressed as two individual peptides: a transactivation domain
(TAD) and a DNA binding domain (DBD). The two peptides can reconstitute a sequence-
specific transcriptional activator if they are brought together via a non-covalent
interaction. This interaction is achieved by a dimerizer, a cell-permeant organic molecule
with two separate motifs that each bind with high affinity to a specific protein module.
The dimerizer, which is provided with the kit, is a chemically modified derivative of
rapamycin, and it is non-toxic to cells or mice if administered below a certain dosage
limit. The DNA binding domain of the ARIAD transcription factor recognizes a unique
composite DNA sequence called ZFHD, which we inserted in the C/EBPβ promoter in
the place of the CRE elements (figure 3.9).
Figure 3.8: Production of NO by
macrophages. Thioglycollate-elicited
peritoneal macrophages were cultured
for 48h in the absence or presence of
IFNγ and/or LPS. NO release was
determined. n=3. t(*)=0.004. Values
were normalized to the cell number,
quantified by MTT staining (see
Materials and Methods).
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A.
B.
C.
Our aim was to create a mouse expressing the ARIAD transcription factor in a time
and tissue conditional manner. Before proceeding with the cloning of the mouse, we
checked whether the system could work in vitro, on cells transfected with our β∆CRE
targeting vector and an expression vector for the ARIAD transcription factor.
Q2bn cells were transfected with the retroviral vector encoding the ARIAD
transcription factor (pL2N2ARIAD), a reporter plasmid with the GFP gene directly
downstream of the ZFHD binding site, and the β∆CRE-neo targeting vector (figure 3.1B)
or the β∆CRE vector with the Neo cassette floxed out (figure 3.1D). The cells were
treated with the dimerizer (20nM) for 24h, and then on one hand they were analyzed by
FACS to detect GFP expression (figure 3.10A), and on the other protein extracts were
analyzed by western blot to detect the expression of C/EBPβ (figure 3.10B).
The green fluorescence, detected only in the sample where the dimerizer had been
added, tells us that the system doesn’t leak, since the functional activity of the ARIAD
transcription factor is entirely dependent on the presence of the dimerizer. The western
blot takes us to a similar conclusion, since expression of C/EBPβ is obtained only when
the C/EBPβ with the ZFHD in the promoter is transfected together with the ARIAD
vector and the dimerizer is present (lanes 9 and 10). Moreover, the western shows that we
can induce C/EBPβ protein expression with this system. The Neo cassette in the β∆CRE-
neo construct does not interfere with C/EBPβ expression because the ZFHD motif is
downstream from it. Therefore we can conclude that the cis ZFHD motif is necessary and
TAD
C/EBPβ
ZFHD
drBD
drBD
DBD
C/EBPβ
ZFHD
drug
C/EBPβ
ZFHD
Figure 3.9: Schematic representation of
the ARIAD transcriptional activity.
A. The ARIAD transcription factor
comprises 2 separate peptides. One is a
transactivation domain (TAD) and the other a
DNA binding domain (DBD). Both peptides
also have a drug binding domain (drBD). The
DBD recognizes a specific sequence (ZFHD)
which has been cloned in the C/EBPβ
promoter. B. The two subunits of the ARIAD
transcription factor cannot interact unless a
drug (or dimerizer) is supplied to the system.
C. The drug will bridge the two peptides and
the TAD can now activate C/EBPβ
transcription.
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sufficient for the activation of a gene in a system where the ARIAD transcription factor is
expressed and the dimerizer is supplied.
A.
B.      1    2     3     4      5     6     7     8     9   10
Figure 3.10: In vitro assay of the ARIAD system. A . Q2bn cells transfected with
pL2N2(ARIAD) and a ZFHD-GFP plasmid not treated (left panel) or treated (right panel) with
dimerizer were analyzed by FACS to detect green fluorescence. B. Western blot on transfected
Q2bn cells. C/EBPβ (LAP higher band, and LIP lower band) was detected with the ∆198 α-
C/EBPβ antibody.
3.2.1 Generation of the R26(ARIAD) Knockin Mouse Line
In order to use the ARIAD system in the β∆CRE mouse, we decided to make a mouse
line where the ARIAD transcription factor is cloned in the first intron of the Rosa26
(R26) gene. Rosa26 is ubiquitous, and the disruption of its gene does not affect the
tissues in any known way (Soriano et al., 1999). The construct provided by ARIAD
ensures that the transcription factor cassette is expressed from the retroviral LTR on a
bicistronic transcript. The first cistron carries the gene for the transactivating peptide, and
the second, separated from the first by an IRES derived from the encephalomyocarditis
virus, encodes the gene for the DNA binding domain (pL2N2(ARIAD) in figure 3.11). To
have an inducible tissue specific expression of C/EBPβ using the ARIAD system in the
mouse, we inserted a stop cassette, in the form of the Neo gene followed by its poly(A)
tail, between the genes encoding the two individual ARIAD peptides. This way, if Cre
recombinase is not expressed in a particular tissue, then only the TAD peptide will be
expressed, and alone it will be unable to transactivate the C/EBPβ gene. If, on the other
1 plain
2 pBS-C/EBPβ
3 β∆CRE-neo
4 β∆CRE
5 pBS-C/EBPβ + ARIAD
6 β∆CRE-neo + ARIAD
7 β∆CRE + ARIAD
8 pBS-C/EBPβ + ARIAD + dimerizer
9 β∆CRE-neo + ARIAD + dimerizer
10 β∆CRE + ARIAD + dimerizer
GFP
0.56% 42.64%
LAP
LIP
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hand Cre recombinase is expressed in a given tissue, the Neo cassette with its stop
cassette will be floxed out, and we will obtain equal transcription of both the TAD and
DBD peptides. However, transactivation will only be obtained in the presence of the
dimerizer.
            A.
C.
Figure 3.11: Cloning procedure for the R26(ARIAD) mouse. A. The ARIAD construct was
transferred in pBS-SALPA, which carries R26 splice acceptor (sA) and polyadenylation site (pA).
B. ARIAD homology arms were cloned in pSVkeo-X1 flanking the Neo cassette. The Neo
cassette was inserted in the pSALPA(ARIAD) vector between the TAD gene and the IRES
sequence by ET recombination. C. The XbaI fragment containing the complete ARIAD cassette
was inserted in the R26-1 targeting vector, and used to target the R26 locus.
The pL2N2(ARIAD) construct was transferred into the pBS-SALPA vector, a plasmid
which carries a splice acceptor and a polyadenylation site from the original R26 gene
separated by a polycloning site (figure 3.11A). The splice acceptor is necessary for the
B.
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ARIAD cassette to be correctly spliced from the first intron of the R26 gene. Next, The
insertion of the Neo cassette between the TAD and DBD genes was performed by ET
recombination between the pSVKeo-X1 plasmid, in which homology arms (A and B)
were cloned on either side of the Neo cassette, and the pSALPA(ARIAD) construct
(figure 3.11B). Finally, the whole ARIAD cassette was transferred into the targeting
vector for the R26 gene. This vector, called R26-1, has homology arms that enable the
insertion of the exogenous cassette in the first intron of the R26 locus (figure 3.11C).
The R26-1(ARIAD) construct was sequenced to make sure that it had been correctly
cloned, and it was transformed in the XL-1 Cre bacterial strain, to check that the Neo
cassette would be floxed out as expected (data not shown). The R26-1(ARIAD) targeting
vector was transfected in ES cells, which were put in selection with G418. The clones
were screened by Southern blot analysis (see Materials and Methods). Seven
heterozygous clones were obtained (figure 3.12), and one was injected in mouse
blastocysts.
We obtained germline transmission of the R26(ARIAD) knockin. The mouse line is
now in the process of being crossed to several tissue specific Cre lines, and screened, to
determine whether the ARIAD system works in vivo, as well as it does in vitro.
Figure 3.12: Example of R26(ARIAD) positive clone. The
southern is performed with an EcoRI digestion and the probe is
external to the targeting construct. The wild type band is about
13kb in size, whereas the knockin band is around 4.9kb (in the
third lane is an example of a heterozygous clone).
13kb
4.9kb
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3.3 Study of C/EBPβ Phosphorylation Mutants
If the sequences of the C/EBPβ genes from different species are aligned, four regions
on the sequence stand out as highly conserved. The first two conserved boxes are the
conserved regions in the transactivation domain, and at the C-terminus the bZIP domain
is notoriously conserved among all the C/EBP family members. The fourth region is
placed in the RD2 domain (see Introduction). This serine-rich region carries several
phosphorylation sites, some of which are still debated upon (e.g. the serines upstream of
Thr188), and others that are by now fully acknowledged (e.g. the Thr188) (figure 3.13).
We chose to develop these studies further, with the advantage of using genetically
engineered animal models.
rLAP AYLGYQATPSGSSGSLSTSSSSSPPGTPSPADAK
||||||||||||||||||||||||||||||||||
mLAP AYLGYQATPSGSSGSLSTSSSSSPPGTPSPADAK
||||||| ||||||||||||||||||||||||||
hLAP AYLGYQAVPSGSSGSLSTSSSSSPPGTPSPADAK
 ||||| ||||||| ||||||||||||| |
cLAP SYLGYQSVPSGSSGNLSTSSSSSPPGTPNPSESSK
T188A                      *
3S/A               *   *   *
Figure 3.13: Sequence alignment of the C/EBPβ RD2 region. RD2 domains of rat, mouse,
human and chicken were aligned. Thr188 (in bold) was mutated to alanine to generate the T188A
mutant. The three underlined serines were all mutated to alanine to create the 3S/A mutant.
Thr188 of the mouse C/EBPβ  has been shown to be a target for MAPK
phosphorylation (Nakajima et al., 1993) and to be involved in skin tumorigenesis (Zhu et
al., 2002). However, all the studies on this phosphorylation site were done in vitro.
Therefore we proposed to gain further insight on the physiological role of Thr188 by
making a mutant mouse line, where the threonine was substituted by an alanine. In
parallel, we chose to make a mouse model in which serines 176, 180 and 184, that have
recently been shown to correspond to GSK3β phosphorylation sites (Zhao et al., 2005;
Tang et al., 2005) were mutated to alanine.
3.3.1 Generation of the T188A and 3S/A Mutants
To make point mutations in the RD2 region, we chose the strategy of cloning a DNA
linker, with the mutations, inside the C/EBPβ gene. In this region, there are no suitable
restriction sites for inserting the linker, so we created two unique restriction sites by
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making silent mutations. In particular, nucleotides 511-516, which are normally agc ggc
(a serine and a glycine), were changed into tcc gga (always a serine and a glycine), which
creates a BspEI restriction site. This mutation was made by amplifying by PCR a
fragment of the C/EBPβ gene spanning from the start site to the mutated nucleotides,
using an antisense oligonucleotide that carried the mutation. In a similar fashion,
nucleotides ccc ggc (557-562)(a proline and a glycine) were changed into ccc ggg, which
creates a XmaI restriction site without altering the amino acidic sequence. In this case a
mutated sense oligo was used to amplify a fragment from the point of mutation to the
C/EBPβ stop codon. To make the 3S/A mutant, a DNA linker (created by annealing sense
and antisense oligos) with the 3S/A mutations was ligated between the BspEI and XmaI
restriction sites. In the case of the T188A mutant, the point mutation was made directly
on the same oligo that was used to create the XmaI site, and a wild type linker was cloned
between the BspEI and XmaI restriction sites (figure 3.14).
A.
B.
C.
Figure 3.14: Schematic representation of the point mutations made on the C/EBPβ gene. A.
Close-up of the RD2 domain on the wt C/EBPβ. The amino acids we want to mutate are
highlighted in red. B. Insertion of the 3S/A linker between the BspEI and XmaI artificially
created sites. C. Insertion of a wt linker between BspEI and XmaI. The T188A point mutation
was created together with the XmaI restriction site.
The mutated clones were checked by sequencing and by restriction mapping (data not
shown).
490/164                                                       520/174                                                   550/184
ctg ggc tac cag gcg acg ccg agc ggc agc agc ggc agc ctg tcc acg tcg tcg tcg tcc agc ccg ccc ggc acg ccg agc
 L    G      Y   Q    A    T    P     S    G    S   S    G    S     L   S   T    S    S    S    S    S    P     P    G    T    P    S
wt
490/164                                                                                                                                                                              562/188
ctg ggc tac cag gcg acg ccg tcc gga                                                                                 ccc ggg acg ccg agc
 L    G      Y   Q    A    T    P     S    G                                                                                    P    G    T    P    S
BspeI XmaI
agc agc ggc gcc ctg tcc acg gcc tcg tcg tcc gcc ccg
  S   S    G    A     L   S   T    A    S    S    S    A   P
3S/A
490/164                                                                                                                                                                              562/188
ctg ggc tac cag gcg acg ccg tcc gga                                                                                 ccc ggg gcg ccg agc
 L    G      Y   Q    A    T    P     S    G                                                                                    P    G    A    P    S
agc agc ggc agc ctg tcc acg tcg tcg tcg tcc agc ccg
  S   S    G    S     L   S   T    S    S    S    S    S    P
BspeI XmaI
T188A
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3.3.2 Anderson on the 3S/A and T188A Phosphorylation Mutants
Before proceeding to make a mouse, we analyzed the phosphorylation mutants in
vitro, in the attempt to find a model system that could help us answer some basic
questions on the nature of these sites.
In 1999, Ross et al. demonstrated that C/EBPα is a target for GSK3β
phosphorylation. This was done by treating 293T cells with lithium, a natural inhibitor of
GSK3β. The region in which C/EBPα is phosphorylated, just upstream from the bZIP
domain, corresponds to where our three serines are located in the C/EBPβ gene.
Moreover, GSK3β is known to phosphorylate serines or threonines that are positioned
four amino acids upstream from another serine or threonine, and this is the pattern in
which C/EBPβ serines 176, 180 and 184 fall into.
The 3S/A and T188A C/EBPβ mutants were cloned into the pBabePuro retroviral
vector, which was used to infect NIH3T3 mouse fibroblasts. The cells were treated with
LiCl following the protocol in Ross et al., and the protein extracts were separated on an
Anderson protein gel, a SDS-free acrylamide gel in which proteins migrate according to
their charge rather than their molecular weight (figure 3.15).
There is a clear shift in C/EBPβ migration between wt and 3S/A, confirming our
hypothesis of there being one or more phosphorylations on the three mutated serines. The
T188A mutant migrates as a duplet. The protein is seemingly present in a double,
phosphorylated and unphosphorylated, state. What we expected from this experiment was
to see a shift in the migration of the wild type C/EBPβ treated with lithium, similar to the
shift of the 3S/A mutant. This does not seem to be the case, although there is a very faint
band in the wt + Li sample at the right level. Considering the recent publications that
showed, although somewhat controversially, that some of these serines are GSK3β
targets (Zhao et al., 2005; Tang et al., 2005), it is probable that our experiment wasn’t
stringent enough. Possibly, NIH3T3 fibroblasts are less sensitive to lithium than the 293T
cells used in the work by Ross and collaborators. However, this Anderson gel gave us
interesting insights on the possible mechanism of phosphorylation, which will be
discussed further on in this thesis (see Discussion).
Li
wt T188A 3S/A pBP
 -     +       -     +        -      +       -     +
Figure 3.15: Anderson on C/EBPβ
phosphorylation mutants. NIH3T3 cells
infected with wt C/EBPβ, T188A, 3S/A
or empty vector (pBP), were treated (+) or
not treated (-) with 25µM LiCl for 48h.
Cell lysates were run on an Anderson gel.
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3.3.3 In Vitro Functional Assays on the C/EBPβ Phosphorylation Mutants
In the attempt to find a functional role for the 3S and T188 phosphorylation sites, we
screened our mutants for their capability to carry out some of the known functions of the
C/EBPβ transcription factor.
In the first place we asked whether our mutants were capable of transactivating a
reporter gene. Past findings, in fact, suggested that the RD2 domain is an important
region, involved in regulating C/EBPβ transactivational activity (Kowenz-Leutz et al.,
1994). We performed luciferase reporter assays using mim-1, a known target of C/EBPβ
transcription, as reporter gene. Q2bn quail fibroblasts were transfected with wild type
C/EBPβ , 3S/A or T188A expression vectors along with the luciferase reporter,
normalizing with β-gal (figure 3.16A). The experiment was repeated in a similar way in
NIH3T3 mouse fibroblasts using the Dual Luciferase Assay kit (Invitrogen) (figure
3.16B)).
A.           B.
Figure 3.16: Luciferase reporter assays on C/EBPβ and the phosphorylation mutants. The
mim1 promoter was used for the reporter gene. A. Q2bn cells transfected with empty vector, wild
type C/EBPβ or the mutants were tested for luciferase and normalized with β-gal. B. NIH3T3
cells transfected with empty vector, wild type C/EBPβ or the mutants were tested with the Dual
Luciferase Assay Kit. n=2.
It is evident that the mutations in the phosphorylation sites do not impair C/EBPβ’s
transactivational activity. On the contrary, it appears that the activity is enhanced. This
result is not consistent for the T188A mutant, but it is significant in both assays for the
3S/A mutant.
Next, we asked whether the phosphorylation mutants were capable of inducing
NIH3T3 differentiation into adipocytes when treated with an appropriate hormonal
cocktail. In fact, it is known that C/EBPβ  overexpression in NIH3T3 cells triggers
adipogenesis when a cocktail composed of insulin, IBMX (isobuthylmethylxanthine), and
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dexamethasone is added to the culture medium (Wu et al., 1995). NIH3T3 fibroblasts
infected with pBP, wild type C/EBPβ, T188A and 3S/A retroviral vectors, were treated
with the above described differentiation medium for two days, and then shifted to normal
growth medium. After three additional days in culture, all the cells expressing C/EBPβ,
whether wild type or mutated, had differentiated into adipocytes, whereas the pBP control
sample did not (figure 3.17). Adipocytes were stained with Oil Red O, a lipid-specific
dye, to visualize fully differentiated cells. The dye was then extracted from the cells with
isopropanol and absorbance was measured to quantify adipogenesis. As expected, there
was no significant difference between the mutants and the wild type control (not shown).
While trying to make the experimental conditions more stringent, we observed that
differentiation could be induced with equal success if the cells were treated with
dexamethasone alone, as long as C/EBPβ was overexpressed. However, also in this case
there was no difference in the differentiation capacity between the wild type C/EBPβ and
the phosphorylation mutants (data not shown).
Figure 3.17: Differentiation assay on NIH3T3 fibroblasts. Cells were infected with empty
vector (pBP), wild type C/EBPβ (wt) and mutant clones (T188A and 3S/A). Cells were grown in
normal growth medium (GM, first row), or in adipocyte differentiation medium (Ins+Dex, second
row). In the bottom row, differentiated cells from row 2 were stained with Oil Red O.
Finally, we asked whether the phosphorylation sites on the RD2 domain could be
important for mediating protein-protein interaction between C/EBPβ and coactivators of
C/EBPβ transcription. As a working model, we took the interaction between C/EBPβ and
Cyclin D1. Indeed, C/EBPβ was shown to be involved in the regulation of genes affected
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by oncogenic cyclin D1 overexpression (Lamb et al., 2003). In their work, Lamb and
coworkers show that cyclin D1 and C/EBPβ physically interact, so we tried to repeat the
experiment with our phosphorylation mutants (figure 3.18).
Once again, the phosphorylation mutants seem to be perfectly functional in vitro.
In conclusion, we can say that the T188 and the 3S phosphorylation sites are involved
in modulating the transactivational activity, although this doesn’t seem to influence
C/EBPβ’s role in inducing adipogenesis. Moreover, the phosphorylation sites do not
seem to be involved in mediating protein-protein interaction (at least not in the specific
interaction with cyclin D1). These findings seem to exclude a role of the RD2 domain in
enabling configurational changes that can either permit or block the transcription factor’s
functional activity.
As often happens for subtle mutations, the best way to find the functional role of the
3S and T188 phosphorylation sites is to study them in physiological conditions, and
therefore to make a mouse model out of the 3S/A and T188A mutants.
3.3.4 Generation of the 3S/A and T188A Mouse Lines
The C/EBPβ phosphorylation mutants were cloned in the NS-RI vector (courtesy of
A. Leutz), which is a plasmid that carries all of the coding sequence of C/EBPβ plus part
of the promoter and the 3’ utr. About ten nucleotides upstream of the start codon, this
plasmid has an ectopic EcoRI restriction site, which is particularly useful for genotyping.
The point mutations were cloned into NS-RI by substituting the BstBI-PstI fragment of
the wild type C/EBPβ with the same fragment from the phosphorylation mutants (figure
3.19A). Next, the whole C/EBPβ cassette from NS-RI was transferred into the pTV-flox
targeting vector (also courtesy of A. Leutz) with NotI and SalI (figure 3.19B). The pTV-
flox  plasmid encodes all of the C/EBPβ  genomic clone, with a floxed Neo cassette
inserted in the 3’ utr of the C/EBPβ gene. Moreover, pTV-flox has a thimidine kinase
(TK) cassette, which enables an additional negative selection strategy on the ES cells (by
Figure 3.18: Physical interaction between cyclin
D1 and the C/EBPβ  phosphorylation mutants.
HA-tagged cyclin D1 was transfected in 293T cells in
combination with C/EBPβ , T188A, 3S/A and
C/EBPα (as a control) expression vectors. Whole cell
lysates were immunoprecipitated with an antibody
against C/EBPβ and the Western blot was probed
with anti-HA and anti-C/EBPβ antibody. A non-
specific band is recognized just above C/EBPβ.
input
CycD1-HA
C/EBPβ
T188A
3S/A
C/EBPα
 +       +       +       +
 +        -        -        -
 -        +        -        -
 -         -       +        -
 -         -        -        +
IP
C/EBPβ
CycD1
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administration of gancyclovir) if the selection by neomycin resistance isn’t stringent
enough.
A.
B.
Figure 3.19: Schematic representation of 3S/A and T188A cloning procedure. A. Point
mutations were inserted in the NS-RI plasmid by exchanging the BstBI-PstI fragment from this
plasmid with the one from the previously described mutants (figure 3.14). The red asterisk
indicates point mutations, whether 3S/A or T188A. B. The NotI-SalI fragment from NS-RI was
then cloned into pTV-flox.
The pTV-flox(3S/A) and pTVflox(T188A) targeting constructs were transfected into
ES cells and clones were selected by resistance to G418. About 200 clones were picked
for each construct and screened by Southern using the same EcoRI-XbaI probe used for
the β∆CRE ES cells, which is external to the targeting construct, on an EcoRI digestion.
The mutant gives a band of 2.9kb, thanks to the presence of the ectopic EcoRI site just
before the C/EBPβ start site, whereas the wild type is around 4.9kb long. We obtained
one positive clone for the 3S/A mutant, and four for the T188A. These clones were
double checked with a different Southern strategy. The ES cell DNA was digested with
XbaI and BspEI, and screened with a SphI-XmaI probe, internal to the C/EBPβ gene. The
mutants are characterized by a 2.8kb band, due to the ectopic BspEI restriction site,
which was put in the C/EBPβ coding sequence by silent mutation to make the point
mutations in the first place (figure 3.14). The wild types, instead, give a 3.5kb band. In
figure 3.20 are examples of the two Southern strategies.
NotI SalI
cds
EcoRI
BstBI PstI
pBS-NS-RI
*
Neo
3’ utr (right arm)
NotI SalIXbaI
promoter (left arm)
TK
pTVflox
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A.                           B.
A positive ES cell clone for each construct was injected in mouse blastocysts.
Germline transmission was obtained for both mutants, which are now established mouse
lines. The Neo cassette was excised from the 3’utr of the C/EBPβ gene by crossing the
lines with a deleter-Cre mouse.
Both mouse lines were analyzed for female fertility. Fertility tests were set up in a
similar way to the one described for the β∆CRE line. Homozygous females were fertile
in both mutants (data not shown).
3.3.5 T188A and 3S/A Protein Expression and Migration in Animal Tissues
Protein extracts were made from several different tissues from the T188A and 3S/A
mice. In the first place, we checked how the endogenous mutant protein would migrate
on an Anderson gel (figure 3.21).
The pattern of migration of the phosphorylation mutants is similar to what we obtained in
vitro (see figure 3.15). In addition, we now have heterozygous samples, which are useful
to compare the relative quantities of wild type and mutant protein. For example, in the
3S/+ sample of the lung, and possibly the fat, the wild type allele of C/EBPβ seems to be
more than the mutant allele. This could be explained by a relative instability of the 3S/A
protein in these tissues. All the TA/+ samples show a stronger band corresponding to the
wild type allele. This is not surprising, since we know that T188A migrates as a duplet,
and that one band in the duplet migrates at the same height as the wild type C/EBPβ,
thereby enriching that particular band. However, it is interesting to note that in all the
Figure 3.20: Southern analysis on 3S/A and
T188A clones. A. Example of a positive clone
screened by an EcoRI digestion and the EcoRI-
XbaI external probe. B. Example of a positive clone
counterscreened by a BspEI-XbaI digestion and the
SphI-XmaI internal probe.
liver
skin
lung
fat
-/-     +/+      3S/+   3S/3S   TA/+  TA/TA
Figure 3.21: Anderson Western blot on
phosphorylation mutant tissues. Whole cell
extracts were made out of the indicated tissues,
and run on an Anderson gel. The blot was
probed with an anti-C/EBPβ antibody.
4.9kb
2.9kb
2.8kb
3.5kb
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TA/TA tissues except the fat, the band corresponding to the unphosphorylated form of
the protein is more abundant than the phosphorylated. It is possible that in the fat C/EBPβ
phosphorylation is regulated in a different way in comparison to other tissues.
To analyze the T188A tissues, we had the additional advantage of the existence of an
antibody specific for the phosphorylated Thr188. Liver tissue extracts were run on a
traditional SDS-PAGE, and the western was probed with the anti-phosphoT188-C/EBPβ
antibody (figure 3.22).
C/EBPβ  phosphorylated on Thr 188 is clearly missing in the TA/TA samples, whereas
the anti-C/EBPβ antibody shows that the protein is there.
3.3.6 Study of the Phosphorylation Mutants in Macrophages
Since the β∆CRE mice gave interesting results on the role of C/EBPβ  in the
macrophages, we were curious to know whether phosphorylation on the RD2 domain was
important in regulating the transcription factor’s activity in these cells.
Primary bone marrow-derived macrophages were treated overnight with IFNγ and
then with IFNγ/LPS for four hours. cDNA was made from total RNA extracts, and the
samples were then analyzed by RT-PCR to see whether there was an anomaly in the
expression of the C/EBPβ IFNγ/LPS-dependent target genes (i.e. arginase 1, Msr1,
IL13α1). In the T188A macrophages the expression of the C/EBPβ target genes, as well
as that of C/EBPβ itself was similar in wild types and TA/TA samples. All these genes
were regularly induced in response to IFNγ/LPS treatment (data not shown). Surprisingly,
in the 3S/A macrophages there was a misregulation of C/EBPβ as well as some of its
target genes, but not an inhibition of induction in the LPS-treated samples, as was the
case for the DC/DC mice, but rather an excessive upregulation (figure 3.23).  This was
the case for the expression of C/EBPβ, arginase 1 and IL13α1, but not for Msr1 (not
shown). These results suggest an autoregulatory role for the three serines in the RD2
domain. In particular, the phosphorylation on these residues should enhance the
inhibitory effect of C/EBPβ  on its own transcription. The absence of these
phosphorylation sites is sufficient to abrogate the autoregulational capability of the
transcription factor. The overexpression of some target genes of C/EBPβ obtained with
the IFNγ/LPS-treated 3S/3S sample can either be a direct consequence of the
+/+ TA/TA -/-
P(T188)C/EBPβ
C/EBPβ
Figure 3.22: Detection of T188-
phosphorylated C/EBPβ on liver extracts.
Western blot was done using α-P(T188) and
α-C/EBPβ antibody.
RESULTS
61
overexpression of the mutated C/EBPβ , or it can be explained by a higher
transactivational potential of this mutant.
   A.                                                          B.
 C.
Since we have shown that there is a strong over-induction of C/EBPβ in the LPS-
treated 3S/3S macrophages at the transcriptional level, we were interested to see what
happened at the protein expression level. 3S/A macrophages were obtained from bone
marrow as usual, and were treated with IFNγ/LPS for four hours. Whole cell extracts
were separated on an Anderson gel and the blot was probed for C/EBPβ (figure 3.24). In
this experiment, we can see that IFNγ/LPS treatment does not change the phosphorylation
of the wild type C/EBPβ, and the upregulation is probably not strong enough to be
detected by Western. However, it is clear that the expression level of the IFNγ/LPS-
treated 3S/3S and 3S/+ protein is higher in comparison to the unstimulated counterpart.
These results further support the theory that serines 176, 180 and 184 are involved in the
C/EBPβ autoregulatory loop.
Figure 3.23: Expression of C/EBPβ and
its target genes in 3S/A macrophages.
cDNA from 3S/A macrophages treated or
not treated with IFNγ/LPS was screened by
RT-PCR to detect the expression levels of
C/EBPβ (A)(t=0.013), IL13α 1 (B)
(t=0.033), and arginase 1 (C) (t=0.045).
n=6 and 3.
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Figure 3.24: Anderson on IFNγ/LPS-treated 3S/A macrophages. 3S/A IFNγ/LPS-treated or
not treated macrophage whole cell extracts were run on an Anderson gel. The blot was probed
with an anti-C/EBPβ antibody. In the bottom panel is a non-specific protein recognized by the
same antibody, which can be used for normalization.
+/+-/- 3S/+ 3S/3S
IFNγ/LPS-          +            -              +           -              +           -            +
C/EBPβ
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4. DISCUSSION
4.1.1 CREB is a Direct Activator of C/EBPβ Gene Transcription in Macrophages
In the first tissues where we measured C/EBPβ expression levels (liver, brain and fat;
figure 3.2), we never obtained an inhibition of C/EBPβ expression due to the absence of
the CRE elements. This does not necessarily mean that CREB is not required at all for
C/EBPβ transcription in these tissues, but simply that it is not necessary for basal
transcription, whereas modified environments, such as activated states should be further
investigated. Although CREB has been shown to regulate C/EBPβ transcription in the fat
(Zhang et al., 2003), β∆CRE mice do not show an aberrant phenotype in the adipose
tissue, as neither do C/EBPβ knock out mice unless C/EBPβ is depleted in combination
with C/EBPδ (Tanaka et al., 1997). Indeed, C/EBP family members can often be
redundant with one another, taking over the missing member’s function in its absence. In
Nature this ability can have a protective role, but in science it can make it particularly
difficult to dissect the function of one specific C/EBP family member in a given tissue.
In macrophages, C/EBPβ is the predominant C/EBP isoform (Natsuka et al., 1992).
Very low levels of C/EBPδ are expressed, and are probably insufficient to make up for a
deficiency in C/EBPβ. For this reason we chose to work on primary macrophages to
investigate on the role of CREB in regulating C/EBPβ gene transcription.
The first proof that CREB can physically interact with the C/EBPβ promoter comes
from the work of Zhang et al. (2003). In this work a chromatin immunoprecipitation
(ChIP) was performed on 3T3-L1 preadipocytes and MEFs (mouse embryo fibroblasts)
showing that CREB is found on the C/EBPβ promoter at all times, but phosphorylated
(and thus active) CREB is found only after adipogenesis is stimulated in these cells. In
macrophages, past publications have shown a correlation between CREB phosphorylation
and C/EBPβ activation dependent on LPS stimulation (Bradley et al., 2003), but these
observations were never counter-proved by demonstrating the interaction between
transcription factor and promoter in vivo. We did this by performing a ChIP on the J774
macrophage cell line, to detect the presence of CREB on the C/EBPβ promoter in
conditions of macrophage activation by LPS (figure 3.4). Our findings show that CREB
is not on the promoter prior to LPS-mediated activation, as opposed to what is observed
in preadipocytes or MEFs, supporting the notion that the system of a gene’s regulation is
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very specific to the cell type. Moreover, the physical presence of CREB on the C/EBPβ
promoter has been circumscribed to a 140bp DNA stretch that includes the CRE
elements, giving us sufficient confidence that the β∆CRE mutant will abrogate CREB-
mediated regulation of the C/EBPβ promoter.
Primary macrophages are a slightly more complex system than a macrophage cell
line. A strong variability from mouse to mouse can be a drawback to devising
reproducible experiments. For this reason we spent time on finding the best conditions for
activating the macrophages. In our experimental model LPS could upregulate C/EBPβ
expression, but the fold regulation was random from one mouse to the other. We found
that priming the macrophages with IFNγ enhanced the phenotype and reduced variability
significantly. Consequently, except where specified, the results reported are obtained by
the combined effect of LPS and IFNγ activation.
RT-PCR analyses showed that C/EBPβ cannot be upregulated in response to
IFNγ/LPS-stimulation in β∆CRE DC/DC macrophages (figure 3.6). This means that
C/EBPβ induction during macrophage activation is dependent on CREB and its ability to
drive C/EBPβ transcription. However, since we partially deleted the C/EBP binding site
that overlaps with one of the CRE elements, we cannot exclude that the upregulation of
the C/EBPβ gene in response to IFNγ/LPS is also C/EBPβ-dependent.
4.1.2 Novel Targets for C/EBPβ Transcription in Macrophages: Msr1
We took advantage of our experimental model with the β∆CRE macrophages to find
new downstream targets of C/EBPβ transcription in activated macrophages. The results
of the affymetrix were vast and must be analyzed further, however we tried to select the
genes that appeared most interesting and inherent to the macrophage (table 3.1). Through
RT-PCR analysis, we identified three genes that are C/EBPβ-dependent, and these are
Msr1, arginase-1, and IL13α1 (figure 3.7).
Msr1 is the murine homologue of SR-A (the class A human scavenger receptor).
Scavenger receptors are trimeric transmembrane glycoproteins subdivided in six
domains: the N-terminal cytoplasmic, spacer, α-helical coiled-coil, collagenous and C-
terminal domains (Ashkenas et al., 1993). The ligand binding region is in the positively
charged collagenous domain of Msr1. Scavenger receptors were originally defined by
their ability to recognize modified (i.e. oxidized or acetylated) forms of low density
lipoprotein (LDL), and therefore their implication in atherogenesis (see Introduction)
(Brown and Goldstein, 1983). Msr1 deficient mice crossed to ApoE knockouts (which
have high plasma cholesterol and develop atherosclerotic lesions) have higher levels of
plasma cholesterol than controls and still develop atherosclerotic lesions, although
smaller than those of single ApoE knockouts, consisting mainly of foamy macrophages
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(Suzuki et al., 1997). The presence of atherosclerotic lesions and foamy macrophages in
the double knockout mice suggests that other scavenger receptors may also participate.
Liver sinusoidal Kupffer cells express Msr1, and they are believed to protect the body
by scavenging cholesterol and atherogenic particles from the blood compartment, thereby
reducing the accumulation of modified lipoproteins in the interstitial space of the vessel
wall (Van Berkel et al., 1991).
However, scavenger receptors are also able to bind a broad range of polyanionic
ligands, including LPS and lipotechoic acid (LTA), and they have been implicated in host
defense against bacterial infections (Krieger, 1997). Msr1(-/-) mice are more susceptible
to Listeria Monocytogenes infection than wild type controls (Suzuki et al., 1997). In
general, Msr1 can mediate binding and ingestion of a range of microorganisms (Peiser et
al., 2000).
To further support the role of C/EBPβ in regulating Msr1, we would like to assay the
foam cell formation in vitro, on β∆CRE macrophages. This can be done by culturing the
primary macrophages in the presence of modified LDL, and measuring the lipid intake of
the macrophages by Oil Red-O staining. Moreover, we are in the process of screening the
β∆CRE mice for susceptibility to Listeria Monocytogenes infection, which could be, at
least partly, attributed to the incapacity of upregulating Msr1.
4.1.3 Novel Targets for C/EBPβ Transcription in Macrophages: Arginase 1 and
         IL13α1
As mentioned in the Introduction, arginase is an enzyme that converts L-arginine to
L-ornithine and urea. More commonly, in macrophages L-arginine is used by inducible
nitric oxide synthase (iNOS) to synthesize NO, a crucial host-protective, antimicrobial
effector molecule, as well as a potential host-destructive mediator in diverse settings of
immunopathology (Kröncke et al., 1995). Amphibians and mammals express two
isoforms of arginase, called 1 and 2. Both isoforms catalyze the same reaction, but they
are encoded by different genes and differ with respect to cellular distribution and mode of
regulation (Jenkinson et al., 1996). Arginase 1 is a cytosolic enzyme, expressed almost
exclusively in the liver, and arginase 2 is a mitochondrial enzyme with widespread tissue
distribution. In murine macrophages, the arginase 1 isoform is upregulated in the context
of a Th2 immune response, whereas arginase 2 is constitutively expressed (Munder et al.,
1999). On one hand arginase participates in the regulation of NO synthesis by competing
for the common substrate L-arginine (Modolell et al., 1995). On the other, it is involved
in fibrogenic and reparative processes, via collagen synthesis, or antiinflammatory
actions, via production of polyamines, a byproduct of ornithine (Jenkinson et al., 1996).
That C/EBPβ can regulate arginase 1 transcription had already been demonstrated in
vitro (Pauleau et al., 2004; Chowdhury et al., 1996) and suggested in vivo (Sonoki et al.,
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1997). ChIP experiments, performed on the RAW macrophage cell line, detected
C/EBPβ , STAT6 and the coactivator CBP (CREB binding protein) on the arginase
enhancer following IL4 treatment  (Pauleau et al., 2004).
In our experiments, we find an impairment of arginase 1 upregulation in the DC/DC
primary macrophages in response to IFNγ/LPS treatment, which correlates with the
impaired induction of C/EBPβ in the same samples. This not only shows that arginase 1
gene expression is C/EBPβ-dependent in vivo, but we also demonstrate that the activation
initiates through CREB signaling. Since arginase competes with iNOS for the same
substrate, it can be expected that cells in which arginase is downregulated display an
enhanced NO production. This seems to be the case regarding the NO release of β∆CRE
macrophages. When DC/DC macrophages are stimulated with LPS alone, they produce
significantly more NO than the wild type cells (figure 3.8). This is not the case when we
treat the cells with LPS and IFNγ, possibly because the signal to produce NO is much
stronger in these conditions, and the substrate has not yet been totally sequestered by
arginase.
When NO production studies were performed on macrophages from C/EBPβ
knockout mice, peritoneal macrophages were comparable to the wild type controls in
producing NO upon IFNγ/LPS stimulation (Tanaka et al., 1995), but splenic
macrophages from C/EBPβ (-/-) mice previously infected with Candida albicans
displayed a severe impairment in NO production (Screpanti et al., 1995). In neither case
were the macrophages stimulated with LPS alone, but the NO release of the peritoneal
macrophages treated with IFNγ and LPS is comparable to our own results. The
experimental conditions used by Screpanti et al., instead, are not comparable with ours.
Arginase 1 was also shown to be responsive to IL13 signaling (Munder et al., 1999;
Pauleau et al., 2004), and the receptor for IL13 is another gene that we found to be
regulated by C/EBPβ.
Interleukin 13 (IL13) is an immunoregulatory cytokine secreted predominantly by
activated Th2 cells (Minty et al., 1993). IL4 and IL13 are related cytokines that belong to
the same α-helix superfamily, and they share many functional properties. IL13 mediates
its effects via a complex receptor system that includes IL4Rα (IL4 receptor α chain) and
at least two other cell surface proteins, IL13Rα1 and IL13Rα2. Both IL13Rα1 and
IL13Rα2 are members of the hematopoietin receptor superfamily (Miloux et al., 1997).
IL13Rα1 binds IL13 with low affinity by itself, but, when paired with IL4Rα, it binds
IL13 with high affinity and forms a functional IL13 receptor capable of signaling.
Consistent with the fact that IL4 and IL13 share common subunits, they also share
common signaling pathways. Studies in STAT6-deficient mice have revealed that IL13
signaling utilizes the JAK/STAT pathway and specifically STAT6 (Takeda et al., 1996)).
Signaling through IL4Rα/IL13Rα1 is thought to occur via IL4Rα, because both IL4 and
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IL13 stimulation of the complex results in activation of signaling intermediates
characteristic of IL4 responses, including phosphorylation of IL4Rα, insulin-receptor
substrate-2, JAK1, and Tyk2 (Welham et al., 1995). Although IL4 and IL13 have many
overlapping functions, they also have distinct roles. In parasitic infection models, IL13
has a critical role in the Th2-dependent expulsion of Nippostrongyloides brasiliensis
(Urban et al., 1998). Furthermore, IL13 has recently been shown to be a key mediator of
allergic inflammation independent of IL4 in mouse models whereby IL13 blockade
prevented allergen-induced airway inflammation (Grunig et al., 1998).
As was the case for arginase 1, we found a correlation between the impaired C/EBPβ
upregulation in the DC/DC+LPS/IFNγ macrophages and the impaired IL13α1
upregulation in the same conditions. This shows that the upregulation of IL13α1 is
C/EBPβ-dependent. An interpretation of this result is that C/EBPβ has a role in making
the macrophage responsive to IL13 signaling, and that DC/DC macrophages are
consequently unresponsive to such stimulation. This possibility is further discussed
below.
4.1.4 C/EBPβ: a Molecular Switch from M1 to M2 Macrophages?
As was described in the Introduction, macrophages can elicit two opposing immune
responses, depending on the stimuli that they receive. Macrophages induced in Th1-
dominated immune responses, secrete multiple inflammatory mediators (e.g. IL1, IL6 and
TNFα) and are termed inflammatory macrophages or M1 macrophages. M1 macrophages
possess cytotoxic and antimicrobial effector functions based on their ability to produce
NO (MacMicking et al., 1997). On the contrary, M2 macrophages are elicited by the Th2
immune response and display antiinflammatory properties. M2 macrophages produce
arginase 1, which, as mentioned above, will generate urea and polyamines, which nourish
cell growth and promote tissue repair (Jenkinson et al., 1996).
Macrophages are capable of bridging the innate to the acquired immune response
through antigen presentation and the release of cytokines (Unanue and Allen 1987).
Several studies have described an innate response that leads to expansion of suppressor
macrophage populations (Angulo et al., 1995; Atochina et al., 2001). These
immunoregulatory cells, termed natural suppressor (NS) cells, originate from
granulocyte-monocyte progenitors, express Gr1, Mac1 and F4/80 surface markers, and
are capable of inhibiting proliferative responses of naïve or activated T cells. There are
two different subpopulations of NS macrophages. Classically activated macrophages are
IFNγ-dependent, and are found in the bone marrow and peripheral lymphoid organs in
cancer patients and during viral infections (Young et al., 1996; Cauley et al., 2000).
Alternatively activated macrophages are IL4-dependent, and are found in the peritoneal
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cavity of mice in response to the filarial nematode Brugia malayi (Goerdt and Orfanos,
1999).
In our experiments, FACS analyses have shown that our macrophage population
expresses Mac1 and F4/80, which are the traditional macrophage markers, but also, to a
significant extent, Gr1 (figure 3.5). The expression of Gr1 either accounts for the
presence of granulocytes in our culture (an unlikely event considering the culture
conditions), or suggests the presence of NS macrophages. Moreover, the percentage of
Gr1 expression (43%) and that of the two macrophage-specific markers (82% and 57%),
suggests an overlap of at least one of the macrophage markers with Gr1 in these cells.
The fact that C/EBPβ was found in our experiments to regulate the expression of
arginase 1 and IL13α1 receptor subunit, leads us to the tempting supposition that the
transcription factor might activate a molecular mechanism that enables the macrophages
to switch from the M1 to the M2 type. Indeed, arginase 1 is a typical agonist of the Th2-
driven response, and IL13α1 would allow the cell to be responsive to IL13, which is
notoriously a cytokine produced by Th2 cells to drive an M2 antiinflammatory response.
In addition, Atochina and coworkers (2001) have shown that the antiproliferative effect
of NS cells on CD4(+) T cells was dependent on the production of IFNγ and NO. In our
experiments, C/EBPβ-driven arginase and IL13α1 expression is dependent on IFNγ/LPS
stimulation, and we have also shown that in these conditions the cells are able to produce
NO (figure 3.8).
Studies on C/EBPβ knockout mice have shown that with age these mice develop skin
lesions, swelling in the mucosal regions and splenomegaly (Screpanti et al., 1995). These
lesions are more dramatic in mice exposed to pathogens than in mice raised in SPF
conditions. Moreover, these same mice display high levels of IL6, a typical inflammatory
cytokine, in the blood serum compared to their littermate controls. This scenario suggests
a pronounced inflammatory immune response typical of M1 macrophages. In the light of
our experiments, this feature could be interpreted as an underrepresentation of
antiinflammatory M2 macrophages due to the absence of C/EBPβ.
4.1.5 A Broader View and Future Perspectives
One can’t ignore the fact that C/EBPβ has been shown in many cases to regulate
genes involved in the Th1 response, such as COX2, which catalyzes the production of
prostaglandins (Inoue et al., 1995), iNOS (Lowenstein et al., 1993), IL6 (Matsusaka et
al., 1993) and TNFα (Pope, 1994), just to name a few. Our own finding of Msr1 would
probably fall into the same category. However, a transcription factor is not expected to
have a univocal role, particularly because its activity is often modulated by the presence
of other coactivators. Some of the genes stated above were screened by RT-PCR in our
experimental model (e.g. COX2, TNFα and IL6), and found to be regularly induced in
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response to LPS/IFNγ stimulation (data not shown). Most of these genes have binding
sites for the proinflammatory transcription factor NFκB on their promoters, or also PU.1
in the case of COX2. In this case, the C/EBPβ deficiency in the DC/DC macrophages
apparently doesn’t perturb the system, since other potent activators are still present.
Accordingly, also in M2 cells C/EBPβ will act in concert with other coactivators. A good
candidate is STAT6, which was shown to regulate arginase 1 transcription together with
C/EBPβ (Pauleau et al., 2004), and which is essential for IL13-mediated functions in
macrophages (Takeda et al., 1996). Moreover, found in inflammatory zone 1 (FIZZ1)
gene induction in allergically challenged lungs was found to be an IL4- or IL13-driven
process in which STAT6 and C/EBPβ are critical mediators (Stutz et al., 2003).
It is possible that in our experimental model we have a mixture of natural suppressor
M2 cells and M1 macrophages, which respond differently to IFNγ/LPS treatment. It was
shown that activation of NS cells can induce a rapid expansion of these cells in a T
cell–independent manner (Atochina et al., 2001). To understand what sort of populations
we are dealing with it would be interesting to test our macrophages some time after
activation, and see whether the population displays an overall increased level of Gr1, and
perhaps is impaired in NO production. Theoretically, DC/DC macrophages, compared to
the wild types, would be expected to have lower levels of Gr1 and higher NO production
in these conditions. Moreover, additional M2 markers such as IL10 or IL4Rα should be
checked.
A test on β∆CRE mice for susceptibility to parasites, which normally exploit M2
macrophages for a successful infection, could produce interesting insights on the role of
C/EBPβ in facilitating, perhaps, the infection. Since NS cells have been found in
lymphoid organs during viral infections (Cauley et al., 2000), and the replication of HIV-
1 in macrophages seems to be specifically inhibited by the LIP isoform of C/EBPβ
(Tanaka et al., 2005), we are also investigating on the viral susceptibility of the β∆CRE
mice. However, this is work in progress, and nothing can be anticipated yet.
In addition, tumor growth increases NS cell activity (Young et al., 1996).  In recent
publications, C/EBPβ deficient mice were found to be resistant to carcinogen induced
skin tumors (Zhu et al., 2002), and C/EBPβ was also found to be a principal effector of
cyclin D1 activity in mammary gland human cancer (Lamb et al., 2003). In these
publications, the prooncogenic role of C/EBPβ was attributed to a molecular process
taking place in the tumoral cells. However, it would be interesting to investigate whether
C/EBPβ in resident tissue macrophages could have a role in permitting the expansion of
the tumor cells.
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4.2 The Potential and Future Perspectives for the R26(ARIAD) Knockin Mouse
The functionality of the ARIAD transcription factor has been tested in cell lines and
shown to work in a very stringent manner (Pollock et al., 2000; 2002; and our own data,
figure 3.10). The system was also tested in vivo via an intramuscular injection of adeno-
associated viral vectors encoding the ARIAD transcription factor and the target gene
(Rivera et al., 1999). The R26(ARIAD) mouse would be the first example of a transgenic
mouse line expressing the artificial transcription factor. The presence of the Neo cassette
in the middle of the bicistronic transcript allows a tissue specific expression of both
components of the transcription factor dependent on the tissue specificity of the Cre line
the mouse is crossed to. The possibility of feeding the dimerizer to the mouse, or
injecting it intraperitoneally, allows the activation of the transcription factor in a time-
specific manner. Ideally, should the system work, after crossing the R26(ARIAD) mouse
to the β∆CRE line, we would be able to artificially induce C/EBPβ gene expression in
any tissue depending on the availability of a specific Cre mouse line. Furthermore, should
the system prove to be functional, it would be possible to clone the ZFHD motif in the
promoter of any given gene to artificially regulate its transcription.
At the moment we are trying to assay the system in primary cells extracted from the
R26(ARIAD)+/-β∆CRE DC/+ mice. We have crossed the R26(ARIAD) mouse either to
a CD4-Cre (T cell specific) or to a Lys-Cre (macrophage specific) mouse line. The idea is
to purify the T cells and macrophages from each mouse, put them in a culture dish, and
add the dimerizer in the culture medium. After a 24h treatment we harvest the cells and
purify RNA and protein to detect the expression of C/EBPβ. The expression should be
specific to the tissue in which Cre is expressed and to the presence of the dimerizer. If the
system works, the mice are then ready for in vivo approaches, in which we could control
the dependence on C/EBPβ expression in our macrophage experiments. However, more
importantly, the system could be a precious tool to investigate the role of C/EBPβ in
tissue determination during development, for example by an ectopic induction of the gene
in specific tissues.
4.3.1 Migration Pattern of the Phosphorylation Mutants: Can There Be
Cooperativity?
Our phosphorylation mutants target specific phosphoacceptors in the RD2 domain
just upstream from the bZIP domain of the C/EBPβ protein. By running protein extracts
from NIH3T3 cells transduced with the T188A or 3S/A mutants on an Anderson gel, we
were able to confirm the involvement of the mutated sites in phosphorylation events. For
the 3S/A mutant we cannot say whether all three of the mutated serines are normally
phosphorylated. Of particular interest is the migration pattern of the T188A mutant. The
fact that T188A migrates as a duplet, both from in vitro and in vivo whole cell extracts
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(figures 3.15 and 3.21), cannot be attributed only to the T188 point mutation. If the entire
population of the protein is mutated, then it should all migrate in the same way, unless
some labile event, which can modify protein migration, is taking place in this particular
mutant. One band in the duplet migrates like the wild type C/EBPβ, and the other
migrates at the same height of the 3S/A mutant. The labile event, which apparently takes
place in about half of the protein population, could be another phosphorylation, which
requires phosphorylated Thr188 for stability. The most obvious candidates for this
additional phosphorylation are the three serines that are mutated in 3S/A, not only
because of their proximity to Thr188, but also because the lower T188A band migrates
exactly like 3S/A. Additional support to this theory is given by the observation that in the
TA/TA fat tissue extracts, the upper T188A band is more abundant than the lower,
whereas in all the other tissues it is the contrary (figure 3.21). Since it has been shown
that GSK3β phosphorylates C/EBPβ in the fat (Tang et al., 2005), and it is possible that
there is more active GSK3β in the fat than in the other tissues analyzed, this could lead to
a higher amount of phosphorylation on the serines even in the suboptimal condition of the
absence of phosphorylation on residue 188. Analyses done on the phosphorylation of
synthetic peptides carrying the T188A mutation, showed that GSK3β phosphorylation
was impaired, again suggesting a sequential phosphorylation by MAPK and GSK3β
performed on T188 and the preceding serines (Tang et al., 2005). Moreover, the
requirement of a docking site for phosphorylation is characteristic of GSK3β. This kinase
is known to phosphorylate serines or threonines that are located four amino acids
upstream of another threonine, and that are spaced four amino acids one from the other
(see figure 3.13). The fact that the higher band of the T188A C/EBPβ migrates as the
wild type suggests that the wild type C/EBPβ is phosphorylated only transiently on
Thr188, just the time required to enhance GSK3β phosphorylation. This model, although
in many ways supported by Tang et al., still remains to be elucidated by functional
assays.
4.3.2 Controversy Between Published and Personal Data on the Roles of the T188
and 3S Phosphorylation Sites
According to Tang et al. (2005), the mutation of T188 and the GSK3-targeted serines
abolishes DNA-binding and transactivation activities of C/EBPβ. However, our
luciferase assays clearly show that the mutants are not impaired in their transactivational
capacities. On the contrary, our mutants, particularly the 3S/A, have an enhanced
transcriptional activity in vitro (figure 3.16). This finding is in agreement with the work
of Zhao et al. (2005), which shows that mutation of the GSK3β target sites enhances
activity. Moreover, Tang et al. show that by treating 3T3-L1 preadipocytes with
inhibitors of MAPK and GSK3β, adipogenesis is completely blocked and C/EBPβ is
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incapable of binding the aP2 gene (an adipogenic target of C/EBPβ in the fat) promoter.
However, our experiments definitely show that the T188A and 3S/A mutants are
perfectly capable of driving adipogenesis under hormonal stimulation (figure 3.17). The
MAPK and GSK3β inhibitors used by Tang obviously blocked a signaling pathway that
is upstream of C/EBPβ. The conserved and enhanced activity of T188A and 3S/A
discredits the possibility that these phosphorylations in the RD2 domain could somehow
change the three-dimensional configuration of the protein to influence its
transactivational capacities, as suggested by some (Kowenz-Leutz et al., 1994; Williams
et al., 1995). A similar scenario would likely have the effect of on or off, and not
modulate the degree of activity.
4.3.3 Phosphorylation for Autoregulation: Is It a Positive or a Negative Loop?
Our experiments on gene expression in the 3S/A primary macrophages produced very
interesting results on the mechanism of autoregulation of the C/EBPβ gene. The
overinduction of C/EBPβ in the 3S/3S macrophages treated with IFNγ/LPS suggests that
an impairment in autoregulation is taking place. Most likely, 3S/A has lost the capability
of inhibiting (or limiting) its own transcription. This is shown both by the higher
expression of the gene screened at the mRNA level (figure 3.23A), and by the stronger
signal for the 3S/3S samples, particularly the activated ones, on the macrophage
Anderson western blot (figure 3.24). That C/EBPβ is subjected to autoregulation was
already shown by Niehof et al. (2001). The motif on the C/EBPβ promoter responsible
for autoregulation is, as mentioned before, adjacent and partly overlapping with the most
distal CRE element from the start site. In the β∆CRE mice we partly disrupted this
C/EBP binding site by deleting the CRE elements. In all the RT-PCR analyses that we
performed for C/EBPβ expression in the β∆CRE mice, we always observed a slightly
higher basal level of C/EBPβ expression in the untreated DC/DC sample, although
statistically not significant (figure 3.6). This observation supports the idea that a negative
autoregulatory feedback loop can take place on that particular location of the C/EBPβ
promoter in determined conditions, such as quiescence. In addition, the affymetrix in
figure 3.3 shows that the overexpression of exogenous wild type C/EBPβ causes the
downregulation of the endogenous, again proving the existence of a negative feedback
loop.
The higher induction of the C/EBPβ  target genes in the 3S/3S macrophages
stimulated with IFNγ/LPS (figure 3.23B and C) could be explained as being the
consequence of the higher expression of C/EBPβ. However, if we combine this result
with the luciferase assays, it is also possible that the 3S/A mutant simply has a stronger
transactivational capacity than the wild type transcription factor. On the other hand, this
would probably mean that the autoregulatory feedback loop is positive instead of
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negative. In other words, instead of wild type C/EBPβ sitting on the promoter to prevent
further transcription by other transcription factors, it could directly activate its own
transcription, and the 3S/A mutant would be all the more efficient in doing so. The
autoregulatory loop was described as being positive also by Niehof et al. (2001). This
explanation, however, doesn’t take into account the slightly higher basal transcription of
the β∆CRE DC/DC mutant, and the downregulation of the endogenous C/EBPβ in cells
overexpressing an exogenous analog. It is tempting to believe that the 3S/A protein has
stronger transactivational abilities on one hand, but weaker autoinhibitory properties on
the other. Practically, the two mechanisms should be considered distinct, and modulated
perhaps by the interaction with different cooperating proteins.
The vicinity and partial overlap of the C/EBP binding site to the CRE element on the
C/EBPβ promoter may suggest an interaction between C/EBPβ and CREB, which is not
impossible, both being bZIP proteins. If the feedback loop is positive, then the interaction
with CREB would most certainly enhance activation. If it is negative, then maybe
C/EBPβ could mask CREB’s activation site, or rather, the presence of C/EBPβ on the
C/EBP site could be of steric hindrance to the binding of CREB on the CRE element,
without there being any interaction. With the elements that we have, it is difficult to
determine which interpretation is the correct one, and most of what we have said is
reduced to speculation. It will take further studies to have an answer.
4.3.4 The Importance of a Mouse Model
The activity of the T188A mutant doesn’t seem to be reproducibly enhanced. T188A
was comparable to the wild type in one of the two luciferase assays (figure 3.16B), and
also in the ability to autoregulate C/EBPβ gene expression and induce C/EBPβ target
gene expression in the macrophages (not shown). If the theory on the cooperativity
between the T188 and 3S phosphorylation sites is true, then the higher migrating protein
could be sufficient to modulate C/EBPβ activity in the cell, and the phenotype would be
intermediate to wild type-like. However, this would mean that the T188A phosphorylated
on the three serines is dominant on the unphosphorylated, and this takes us back to the
theory of the negative feedback loop. Again, this is pure speculation.
The anti-phospho-T188 antibody was very useful to confirm that the T188A mice
actually carried the intended mutation (figure 3.22). The migration pattern of this protein
remains an intriguing puzzle and we have done our best to interpret it. Cooperativity or
no, we know with certainty that our point mutations have hit distinct phosphorylation
sites. Regarding the 3S/A mutant, we cannot be sure that all three of the mutated serines
are involved in the phosphorylation. However, due to the considerable shift in protein
migration, it is reasonable to believe that at least two of the serines are involved, and
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these would probably be Ser180 and Ser184. Once again, this cannot be asserted for
certain.
The cloning of mice carrying the point mutations has been helpful in clarifying
controversial issues on these phosphorylation sites, and making us confident that we are
not dealing with experimental artifacts. We believe that further studies of the T188A
mouse in vivo will help us understand the role of this MAPK phosphoacceptor in each
cell type and in physiological conditions. This mouse would also be useful to confirm the
findings of Zhu et al. (2002) that the T188 phosphorylation site is involved in the
signaling of oncogenic ras causing C/EBPβ to have an important role in carcinogen-
induced skin tumors. Their studies regarding Thr188, in fact, were based on in vitro
experiments. Moreover, the. tumor model on the T188A mice would be a very useful tool
to uncover the role of this phosphorylation site in respect to C/EBPβ function. For this
reason, we are starting a collaboration with the lab of Robert Smart, which is where Zhu
and coworkers performed their studies.
Taken together, the two projects described in this thesis have produced new insights
on the transcriptional and posttranslational regulation of the C/EBPβ transcription factor.
During these studies we have run into numerous controversies on the published data
regarding the regulation of C/EBPβ’s activity, many of which have been discussed here.
We believe that our studies have in many ways clarified some of these points, thanks to
the use of an in vivo model, which is the nearest we can get to true physiological
conditions. Moreover, we were also able to find novel targets for C/EBPβ transcription in
the macrophage, which were fundamental in suggesting a broader view of the role of
C/EBPβ  in this cell type. It will take more investigation to prove this potential
immunosuppressive role in the macrophages, but most certainly it will have to be done in
vivo.
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